Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Abstract

To provide a pharmaceutical composition of a ketamine derivative and an oral dosage form containing the pharmaceutical composition.SOLUTION: A pharmaceutical composition comprising granules comprising a compound of Formula (1) or a pharmaceutically acceptable salt thereof, hydroxypropyl methylcellulose, microcrystalline cellulose, sodium lauryl sulfate, and magnesium stearate. (R1:H, C1-6 alkyl. R2: amine derivative, substituted oxetane derivative. ) SELECTED DRAWING: None

Description

[Technical Field]

[0001] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 63 / 232,717, filed August 13, 2021, which is incorporated by reference in its entirety.

[0002] The present invention relates to pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile in a two-stage dissolution medium. [Background technology]

[0003] Ketamine derivatives that provide ketamine in a patient's systemic circulation after oral administration are disclosed in U.S. Application Publication No. 2020 / 0231540A1. Oral dosage forms containing ketamine derivatives that provide a zero-order release profile in the gastrointestinal tract after ingestion are desirable. Summary of the Invention

[0004] According to the present invention, the pharmaceutical composition comprises: (a) a compound of formula (1), [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen and C 1-6 alkyl, R 2 is selected from a moiety of formula (2), a moiety of formula (3), a moiety of formula (4), and a moiety of formula (5), [ka] During the ceremony, R 3 is hydrogen, C 1-6 Alkyl, C 7-12 Alkyl arenes and substituted C 7-12 selected from alkylarenes, R4 is hydrogen and C 1-6 alkyl, R5 is hydrogen, C 1-6 alkyl, —C(═O)—R10, and —C(═O)—O—R10, wherein R 10 is C 1-6 Alkyl, C 3-6 cycloalkyl, and —CF3; R 6 is C 1-6 Alkyl and C 1-6 alkoxy; n is an integer from 0 to 3, R7 is hydrogen, C 1-6 Alkyl, -C(=O)-R11, and -C(=O)-OR 10 is selected from: R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl; R 11 -NH2, -CF3, C 1-6 Alkyl, and C 3-6 cycloalkyl; R 9 is hydrogen and C 1-3 a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of alkyl, (b) a controlled release polymer; and (c) anionic sulfate / sulfonate surfactants.

[0005] According to the present invention, an oral dosage form prepared from a pharmaceutical composition according to any one of aspects 1A to 41A.

[0006] According to the present invention, an oral dosage form comprises a pharmaceutical composition according to the present invention.

[0007] According to the present invention, the kit comprises a pharmaceutical composition according to the present invention or an oral dosage form according to the present invention.

[0008] According to the present invention, a method for treating a disease in a patient comprises orally administering a therapeutically effective amount of a pharmaceutical composition according to the present invention or an oral dosage form according to the present invention to a patient in need of such treatment, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0009] According to the present invention, a method for treating a disease in a patient comprises orally administering a therapeutically effective amount of a pharmaceutical composition according to the present invention or an oral dosage form according to the present invention to a patient in need of such treatment, wherein the disease is treated by inhibiting the NMDA receptor.

[0010] According to the present invention, the pharmaceutical composition according to the present invention can be used in the manufacture of a medicament for treating a disorder in a patient, the disorder being selected from a neurological disorder, a psychiatric disorder, and pain.

[0011] According to the present invention, a pharmaceutical composition according to the present invention can be used in the manufacture of a medicament for treating a disease in a patient, the disease being treated by inhibiting the NMDA receptor.

[0012] Those skilled in the art will understand that the drawings described herein are for illustrative purposes only and are not intended to limit the scope of the present disclosure. [Brief explanation of the drawings]

[0013] [Figure 1] 1 shows dissolution profiles of exemplary oral dosage forms provided by the present disclosure. [Figure 2] 1 shows dissolution profiles of example oral dosage forms with and without sodium lauryl sulfate. [Figure 3] 2 shows the regression curves of the dissolution profiles shown in FIG. 1. [Figure 4A] 1 shows the plasma esketamine concentration-time curve after oral administration of a tablet containing 100 mg of Compound (39). [Figure 4B] 1 shows plasma noresketamine concentration-time curves after oral administration of a tablet containing 100 mg of Compound (39). [Figure 5] FIG. 4B is a table summarizing esketamine and noresketamine pharmacokinetic parameters following oral administration of immediate-release and modified-release tablets containing 100 mg of Compound 39 from FIGS. 4A-4B. [Figure 6A] 1 shows plasma esketamine concentration-time curves after oral administration of tablets containing 100 mg, 200 mg, 300 mg, or 400 mg of Compound (39) on day 1. [Figure 6B] 1 shows plasma esketamine concentration-time curves after oral administration of tablets containing 100 mg, 200 mg, 300 mg, or 400 mg of compound (39) on day 7. [Figure 7A] 1 shows plasma noresketamine concentration-time curves after oral administration of tablets containing 100 mg, 200 mg, 300 mg, or 400 mg of Compound (39) on day 1. [Figure 7B] 1 shows plasma noresketamine concentration-time curves after oral administration of tablets containing 100 mg, 200 mg, 300 mg, or 400 mg of compound (39) on day 7. DETAILED DESCRIPTION OF THE INVENTION

[0014] For purposes of the following detailed description, it should be understood that the embodiments provided by the present disclosure may assume various alternative variations and step sequences, unless expressly indicated to the contrary. Furthermore, other than as examples of any operations, or where otherwise indicated, all numbers expressing quantities of ingredients used in the specification and claims, for example, should be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and appended claims are approximations that may vary depending upon the desired properties obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of at least the number of reported significant digits and by applying ordinary rounding techniques.

[0015] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. However, any numerical value inherently contains certain errors necessarily resulting from the standard variation found in their respective testing measurements.

[0016] It should also be understood that any numerical range recited herein is intended to include all subranges subsumed therein. For example, a range of "1 to 10" is intended to have all subranges between (and including) the recited minimum of 1 and the recited maximum of 10, i.e., minimums of 1 or greater and maximums of 10 or less.

[0017] "Controlled-release" pharmaceutical compositions include modified-release, delayed-release, sustained-release, and extended-release formulations. These formulations are intended to release the API from the pharmaceutical composition at a desired rate and / or time and / or at a specific location or locations in the gastrointestinal tract after oral administration by a patient. The USP defines a modified-release system as one in which the course or location of drug release, or both, is selected to achieve therapeutic efficacy or convenience goals not met by conventional IR dosage forms. More specifically, MR solid oral dosage forms include extended-release (ER) and delayed-release (DR) products. DR products release the drug all at once rather than immediately after administration. Modified-release formulations can include delayed release using enteric coatings, site-specific or timed release, such as for colonic delivery, sustained release, including formulations that can provide, for example, zero-order, first-order, or biphasic release profiles, and programmed release, such as pulsatile release and delayed sustained release.

[0018] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment of a moiety or substituent, for example, -CONH2 is attached through a carbon atom.

[0019] "Alkyl" refers to a saturated or unsaturated, branched or straight-chain, monovalent hydrocarbon radical derived by removing one hydrogen atom from a single carbon atom of a parent alkane, alkene, or alkyne. Examples of alkyl groups include ethyl such as methyl, ethanyl, ethenyl, and ethynyl; propyl such as propan-1-yl, propan-2-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-1-yn-1-yl, and prop-2-yn-1-yl; butan-1-yl, butan-2-yl, and 2-methyl-propan-1-yl. Examples of alkyl groups include butyl, 2-methyl-propan-2-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, but-1-yn-1-yl, but-1-yn-3-yl, and but-3-yn-1-yl. The term "alkyl" includes groups having any degree or level of saturation, i.e., groups having exclusively carbon-carbon single bonds, groups having one or more carbon-carbon double bonds, groups having one or more carbon-carbon triple bonds, and groups having a combination of carbon-carbon single, double, and triple bonds. When specific levels of saturation are intended, the terms alkanyl, alkenyl, and alkynyl are used. Alkyl groups include, for example, C 1-6 Alkyl, C 1-5 Alkyl, C 1-4 Alkyl, C 1-3 It can be alkyl, ethyl, or methyl.

[0020] "Alkoxy" refers to the radical -OR where R is alkyl as defined herein. Examples of alkoxy groups include methoxy, ethoxy, propoxy, and butoxy. An alkoxy group is a C 1-6 Alkoxy, C 1-5 Alkoxy, C 1-4 Alkoxy, C 1-3 It can be alkoxy, ethoxy, or methoxy.

[0021] "Arylalkyl" refers to a non-cyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom is replaced with an aryl group. Examples of arylalkyl groups include benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethene-1-yl, naphthobenzyl, and 2-naphthophenylethan-1-yl. When a specific alkyl moiety is intended, the nomenclature arylalkanyl, arylalkenyl, or arylalkynyl is used. An arylalkyl group is a C 7-16 It may be an arylalkyl, for example, the alkanyl, alkenyl, or alkynyl portion of the arylalkyl group may be C 1-6 and the aryl moiety is C 6-10 The arylalkyl group is C 7-16 It may be an arylalkyl, for example, the alkanyl, alkenyl, or alkynyl portion of the arylalkyl group may be C 1-6 and the aryl moiety is C 6-10 The arylalkyl group is C 7-9 It may be arylalkyl, and the alkyl portion is C 1-3 The aryl alkyl group is C 7-16 Aryl alkyl, C 7-14 Aryl alkyl, C 7-12 Aryl alkyl, C 7-10 Aryl alkyl, C 7-8 It may be aryl, alkyl, or benzyl.

[0022] "Bioavailability" refers to the rate and amount of drug that reaches a patient's systemic circulation after administration of the drug or its prodrug to the patient, and can be determined, for example, by assessing the plasma or blood concentration versus time profile of the drug. Parameters useful for characterizing the plasma or blood concentration versus time curve include the area under the curve (AUC), the time to maximum concentration (T), and the like. max ), and maximum drug concentration (C max ) and C maxis the maximum concentration of drug in the patient's plasma or blood after administration of a dose of drug or form of drug to the patient, and T max is the maximum concentration of a drug in a patient's plasma or blood after administration of a dose or form of drug to the patient (C max ) is the time until

[0023] "Oral bioavailability" (F%) refers to the fraction of an orally administered drug that reaches the systemic circulation. Oral bioavailability is the product of the fraction absorbed, the fraction eliminated by the gut wall, and the fraction escaping the liver. Factors that affect bioavailability can be divided into physiological factors, physicochemical factors, and biopharmaceutical factors.

[0024] "Compounds" and moieties disclosed herein include any specific compound within the disclosed formula. Compounds may be identified by either chemical structure and / or chemical name. Compounds are named using the ChemDraw® Ultra 17.1.0.105(19) (CambridgeSoft, Cambridge, MA) nomenclature program. In the event of a conflict between the chemical structure and the chemical name, the chemical structure is determinative of the compound's identity. Compounds described herein may contain one or more stereocenters and / or double bonds and may therefore exist as stereoisomers, such as double bond isomers (i.e., geometric isomers), enantiomers, diastereomers, or atropisomers. Therefore, any chemical structure within the scope of this specification that is depicted in whole or in part with a relative configuration encompasses all possible enantiomers and stereoisomers of the exemplified compound, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure), as well as enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to those skilled in the art.

[0025] The compounds and moieties disclosed herein include optical isomers of the compounds and moieties, their racemates, and other mixtures thereof. In such embodiments, single enantiomers or diastereomers can be obtained by asymmetric synthesis or resolution of a racemate. For example, resolution of a racemate can be achieved by conventional methods such as, for example, crystallization in the presence of a resolving agent, or by the use of chromatography, for example, using a chiral high-pressure liquid chromatography (HPLC) column having a chiral stationary phase. In addition, the compounds include (Z) and (E) forms (or cis and trans forms) of compounds with double bonds, either as single geometric isomers or mixtures thereof.

[0026] Compounds and moieties may also exist in several tautomeric forms, including the enol form, the keto form, and mixtures thereof. Thus, the chemical structures depicted herein encompass all possible tautomeric forms of the depicted compounds. Compounds may exist in unsolvated forms as well as solvated forms, including hydrated forms. Certain compounds may exist in multiple crystalline forms, co-crystalline forms, or amorphous forms. Compounds include pharmaceutically acceptable salts thereof, or pharmaceutically acceptable solvates of any of the foregoing free acid forms, as well as any of the foregoing crystalline forms.

[0027] "Cycloalkyl" refers to a saturated or partially unsaturated cyclic alkyl radical. A cycloalkyl group is a C 3-6 Cycloalkyl, C 3-5 Cycloalkyl, C 5-6 It may be cycloalkyl, cyclopropyl, cyclopentyl, or cyclohexyl. Cycloalkyl may be selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0028] "Disease" refers to any of the diseases, disorders, conditions or symptoms mentioned above.

[0029] "Drug," as defined in 21 U.S.C. § 321(g)(1), means "(A) any article recognized in the official United States Pharmacopoeia, the official Homeopathic Pharmacopoeia of the United States, or the official National Formulary, or any appendix to any of them, and (B) any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals, and (C) any article (other than food) intended to affect the structure or function of the body of humans or other animals..."

[0030] "Ketamine equivalents," such as "mg ketamine equivalents," refer to the amount of ketamine in a ketamine prodrug provided by the present disclosure. The mg ketamine equivalents can be determined by multiplying the molecular weight of ketamine (237.7 g / mol) by the molecular weight of the ketamine prodrug to determine the fractional equivalents of ketamine in the corresponding ketamine prodrug, and then multiplying the amount of ketamine prodrug by the fractional equivalents. For example, the ketamine prodrug 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3) has a molecular weight of 424.9 g / mol, and the corresponding fractional equivalents of ketamine is 0.559 (237.7 / 424.9). Thus, 100 mg of 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate represents the equivalent of 55.9 mg of ketamine. Compound 39, ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-L-valinate, has a molecular weight of 438 g / mol, and 100 mg of compound 39 represents the equivalent of 54.2 mg of ketamine.

[0031] "Ketamine" refers to (S)-ketamine, (R)-ketamine, and their racemic mixture.

[0032] "Norketamine" is the major active metabolite of ketamine and has the following structure: [ka]

[0033] "Norketamine" refers to the (S)-isomer, (noresketamine), the (R)-isomer, and the racemic mixture thereof.

[0034] "Hydrate" refers to the incorporation of water into the crystal lattice of a compound described herein in a stoichiometric proportion, resulting in the formation of an adduct. Methods for producing hydrates include, but are not limited to, storage in an atmosphere containing water vapor, a dosage form containing water, or routine pharmaceutical processing steps such as crystallization (i.e., from water or a mixed aqueous solvent), lyophilization, wet granulation, aqueous film coating, or spray drying. Hydrates can also form from crystalline solvates under certain circumstances upon exposure to water vapor or upon suspension of anhydrous substances in water. Hydrates can also crystallize in more than one form, resulting in hydrate polymorphs.

[0035] "Immediate release" refers to a pharmaceutical composition that releases substantially all of the pharmaceutically active ingredient into the patient's gastrointestinal tract within less than one hour after oral administration, such as within less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, or less than 10 minutes after oral administration. For example, an immediate release dosage form may release more than 90%, more than 95%, or more than 98% of the pharmaceutically active ingredient in the pharmaceutical composition into the gastrointestinal tract within less than one hour, such as within less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, or less than 10 minutes after oral administration. An immediate release pharmaceutical composition may be suitable for administering a pharmaceutically active ingredient that is absorbed into the systemic circulation from the upper gastrointestinal tract.

[0036] A "metabolic intermediate" refers to a compound formed in vivo by metabolism of a parent compound and that further reacts in vivo to release an active agent. The compound of formula (1) is an acyloxyalkyl derivative of ketamine that is metabolized in vivo to provide the corresponding metabolic intermediate. The metabolic intermediate undergoes nucleophilic cyclization to release ketamine and one or more reaction products. Desirably, the reaction products or their metabolites are not toxic.

[0037] The particle size distribution and average particle diameter can be determined by laser diffraction or sieve analysis.

[0038] "Patient" refers to a mammal, for example, a human.

[0039] "Pharmaceutically acceptable" refers to that which is listed, approved, or approvable by a regulatory agency of the Federal or State government, or in the United States Pharmacopoeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.

[0040] "Pharmaceutically acceptable salt" refers to a salt of a compound that possesses the desired pharmacological activity of the parent compound. Such salts include inorganic acids and acid addition salts formed with one or more protonatable functional groups, such as primary, secondary, or tertiary amines, in the parent compound. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Salts can also be formed with organic acids, such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, and benzenesulfonic acid. Salts may be formed with 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, laurylsulfonic acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid. Salts may be formed when one or more acidic protons present in the parent compound are replaced by coordination with a metal ion, such as an alkali metal ion, alkaline earth ion, or aluminum ion, or a combination thereof, or an organic base such as ethanolamine, diethanolamine, triethanolamine, and N-methylglucamine. Pharmaceutically acceptable salts may be hydrochlorides. Pharmaceutically acceptable salts may be sodium salts. For compounds with two or more ionizable groups, a pharmaceutically acceptable salt can include one or more counterions, such as a disalt, e.g., a dihydrochloride salt.

[0041] The term "pharmaceutically acceptable salts" includes hydrates and other solvates, as well as salts in crystalline or non-crystalline form. When a specific pharmaceutically acceptable salt is disclosed, it is understood that the specific salt (e.g., hydrochloride) is an example of a salt, and that other salts may be formed using techniques known to those skilled in the art. Additionally, using techniques generally known in the art, those skilled in the art will be able to convert a pharmaceutically acceptable salt to the corresponding compound, free base, and / or free acid.

[0042] "Pharmaceutically acceptable vehicle" refers to a pharmaceutically acceptable diluent, pharmaceutically acceptable adjuvant, pharmaceutically acceptable excipient, pharmaceutically acceptable carrier, or a combination of any of the foregoing, with which a compound provided by the present disclosure may be administered to a patient, which does not destroy its pharmacological activity, and which is non-toxic when administered in dosages sufficient to provide a therapeutically effective amount of the compound.

[0043] A "pharmaceutical composition" refers to a compound of Formula (1) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable vehicle administered to a patient together with the compound of Formula (1) or a pharmaceutically acceptable salt thereof. Pharmaceutically acceptable vehicles are known in the art.

[0044] A "population of fasted healthy subjects" refers to two or more subjects, such as more than six subjects.

[0045] "C max " refers to the maximum concentration of the analyte.

[0046] "C t " refers to the concentration of the analyte at time t after administration. For example, C 4h refers to the concentration of the analyte 4 hours after administration.

[0047] "T max " is the C value obtained after administering a dose to a subject. max It refers to the time it takes to reach

[0048] "AUC0-last" refers to the area under the concentration-time curve from the time of administration (0 hours) to the last quantifiable concentration.

[0049] AUC 0-inf " refers to the area under the concentration-time curve extrapolated from the time of administration (0 hours) to infinity.

[0050] "AUC 0-t " refers to the area under the concentration-time curve from the time of administration to time t after administration. For example, AUC 0-12h refers to the area under the concentration-time curve from the time of administration to 12 hours after administration.

[0051] "AUC t1-t2 " refers to the area under the concentration-time curve during the time interval from t1 to t2. For example, AUC 2h-6h refers to the area under the concentration-time curve from 2 to 6 hours after administration.

[0052] "t 1 / 2 " refers to the apparent terminal half-life of the concentration-time curve.

[0053] C max , T max , AUC 0-8 , and AUC 0-0inf If the pharmacokinetic parameters of a pharmacokinetic profile for a pharmaceutical formulation comprising are within 80% to 125% of those for the reference pharmacokinetic profile, the pharmacokinetic profile of the pharmaceutical formulation is considered to be bioequivalent to that of the reference pharmacokinetic profile.

[0054] Two dissolution profiles are considered equivalent if the f2 similarity coefficient is greater than 50. Alternatively, dissolution profiles are equivalent if they differ by 10% or less at each sampling time point.

[0055] "Preventing" or "prevention" refers to a reduction in the risk of acquiring a disease or disorder (i.e., preventing at least one of the clinical symptoms of the disease from developing in a patient who may be exposed to or susceptible to the disease, but who has not yet experienced or displayed symptoms of the disease). In some embodiments, "preventing" or "prevention" refers to reducing the symptoms of the disease by administering a compound provided by the present disclosure in a prophylactic manner. The application of a therapeutic agent to prevent or prevent the onset of a disorder is known as "prophylaxis." The compounds provided by the present disclosure can provide superior prevention due to lower long-term side effects over the long term.

[0056] A "prodrug" refers to a derivative of a drug molecule that requires transformation in the body to release the active drug. Prodrugs are often, but not necessarily, pharmacologically inactive until converted to the parent drug. Prodrugs can typically be obtained by attaching a promoiety to a drug via a functional group. For example, referring to the compound of formula (1), an acyloxyalkyl promoiety is attached to the drug ketamine via the amide group of ketamine. The compound of formula (1) is a prodrug of ketamine that can be metabolized in the patient's body to release ketamine.

[0057] A "promoiety" refers to a group attached to a drug, typically a functional group of the drug, via a bond(s) that is / are cleavable under specific conditions of use. The bond(s) between the drug and the promoiety may be cleaved by enzymatic or non-enzymatic means. Under conditions of use, for example, after administration to a patient, the bond(s) between the drug and the promoiety may be cleaved to release the parent drug. Cleavage of the promoiety may proceed spontaneously, for example, via a hydrolysis reaction, or it may be catalyzed or induced by another agent, for example, an enzyme, light, acid, or a change in or exposure to a physical or environmental parameter, for example, temperature, pH, etc. The drug may be endogenous to the conditions of use, for example, enzymes present in the systemic circulation of the patient to whom the prodrug is administered or the acidic conditions of the stomach, or the drug may be supplied exogenously. The acyloxyalkyl derivatives provided by the present disclosure are prodrugs of ketamine. The acyloxyalkyl promoiety has the following structure: For example, for a compound of formula (1), the acyloxyalkyl promoiety has the following structure: [ka] In the formula, R and R 2 is defined as formula (1): The acyloxyalkyl promoiety is cleaved in the systemic circulation, releasing ketamine into the systemic circulation.

[0058] A "solvate" refers to a molecular complex of a compound with one or more solvent molecules in stoichiometric or non-stoichiometric amounts. Such solvent molecules are commonly used in the pharmaceutical arts and are known to be harmless to patients, e.g., water or ethanol. Molecular complexes of compounds or compound moieties with solvents can be stabilized by non-covalent intramolecular forces, such as electrostatic forces, van der Waals forces, or hydrogen bonding. The term "hydrate" refers to solvates in which one or more solvent molecules are water. Methods for producing solvates include, for example, storage in a solvent-containing atmosphere, a dosage form containing the solvent, or routine pharmaceutical processing steps such as vapor diffusion crystallization (i.e., from a solvent or solvent mixture). Solvates can also form from other crystalline solvates or hydrates under certain circumstances upon exposure to or suspension in a solvent. Solvates may crystallize in more than one form, resulting in solvate polymorphism.

[0059] "Substituted" refers to a group in which one or more hydrogen atoms are independently replaced with the same or different substituent(s). Each substituent is independently selected from deuterated alkyl, halogen, -OH, -CN, -CF3, -OCF3, =O, -NO2, C 1-6 Alkoxy, C 1-6 alkyl, -COOR, -NR2, and -CONR2, where each R is independently selected from hydrogen and C 1-6 Each substituent may be independently selected from deuterated alkyl, halogen, -NH, -OH, C 1-3 Alkoxy, and C 1-3 Each substituent can be independently selected from, for example, deuterio, -OH, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, and trifluoromethoxy. Each substituent can be independently selected from, for example, deuterio, C 1-3 Alkyl, =O, C 1-3 Alkyl, C 1-3 Each substituent can be selected from, for example, deuterated, -OH, -NH, C 1-3 Alkyl, and C1-3 It may be selected from alkoxy.

[0060] "Treating" or "treatment" of a disease refers to arresting or alleviating the disease or at least one clinical symptom of the disease or disorder, reducing the risk of acquiring the disease or at least one clinical symptom of the disorder, reducing the onset of the disease or at least one clinical symptom of the disorder, or reducing or reducing the risk of developing the disease or at least one clinical symptom of the disorder. "Treating" or "treatment" also refers to inhibiting the disease either physically (e.g., stabilization of a discernible symptom), physiologically (e.g., stabilization of a physical parameter), or both, as well as inhibiting at least one physical parameter or manifestation, which may or may not be discernible to the patient. "Treating" or "treatment" refers to delaying the onset of the disease or at least one symptom thereof in a patient who may be exposed to or susceptible to the disease or disorder, even though the patient has not yet experienced or displayed symptoms of the disease.

[0061] A "therapeutically effective amount" refers to the amount of a compound that, when administered to a patient for treating a disease, or at least one of the clinical symptoms of a disease, is sufficient to affect such treatment of the disease or its symptoms. A "therapeutically effective amount" can vary depending, for example, on the compound, the disease and / or symptoms of the disease, the severity of the disease and / or symptoms of the disease or disorder, the age, weight, and / or health of the patient being treated, and the judgment of the prescribing physician. An appropriate amount in any given case can be ascertained by one of ordinary skill in the art or can be determined by routine experimentation.

[0062] A "therapeutically effective dose" refers to a dose that provides effective treatment of a disease or disorder in a patient. A therapeutically effective dose may vary from compound to compound and from patient to patient, and may depend on factors such as the condition of the patient and the route of delivery. A therapeutically effective dose may be determined according to routine pharmacological procedures known to those skilled in the art.

[0063] "Vehicle" refers to a diluent, excipient, or carrier with which a compound is administered to a patient. The vehicle can be a pharmaceutically acceptable vehicle. Pharmaceutically acceptable vehicles are known in the art.

[0064] Zero-order drug release kinetics refers to the process of constant drug release from a dosage form. Constant release is defined as the release of the same amount of drug per unit time. For example, zero-order drug release can be expressed by the formula C = C + k × t, where C is the amount of drug released, C is the initial amount of drug in solution, k is a zero-order constant, and t is time. Zero-order drug delivery systems have the potential to overcome the problems associated with immediate release and first-order systems by releasing drug at a constant rate, thereby facilitating maintaining drug concentrations within the therapeutic window for extended periods of time. Zero-order drug release kinetics can limit adverse side effects, reduce dosing frequency, and potentially improve patient compliance.

[0065] Reference is now made to certain pharmaceutical compositions, oral dosage forms, and methods. The disclosed embodiments are not intended to limit the scope of the claims. On the contrary, the claims are intended to cover all alternatives, modifications, and equivalents.

[0066] Pharmaceutical compositions provided by the present disclosure may include granules comprising a ketamine derivative or a pharmaceutically acceptable salt thereof, a controlled-release polymer, and an anionic sulfate / sulfonate surfactant.

[0067] Solid oral dosage forms prepared from the pharmaceutical composition exhibit a zero-order release profile in a simulated gastrointestinal environment. The inclusion of an anionic sulfate / sulfonate surfactant can increase the dissolution rate of the ketamine derivative at high pH and decrease the dissolution rate at low pH.

[0068] Major depressive disorder (MDD) is one of the most common mental disorders, affecting 264 million people worldwide. Depression significantly increases the risk of suicide, and it is the second leading cause of death among adolescents and young adults. Although MDD is common, its pathophysiology is complex. The accepted underlying cause of MDD is based on the monoamine hypothesis, which proposes that depressed patients have reduced concentrations of monoamines, such as serotonin, norepinephrine, and dopamine, at the synaptic gap. This paradigm has led to the development of new pharmacotherapy and monoamine-based pharmacological drug classes for depression, including tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs), among others, and continues to represent the standard of care. However, approximately one-third of patients with MDD do not respond to current antidepressant treatments and are considered to have treatment-resistant depression (TRD).

[0069] Ketamine and esketamine have been shown to be effective in treating major depressive disorder. Ketamine and esketamine have demonstrated a rapid onset of antidepressant activity in patients with treatment-resistant depression. These studies utilized intravenous ketamine and intranasal esketamine, approved for use in Australia in 2021 as SPRAVATO®. These benefits are accompanied by acute, transient (approximately 2 hours) side effects of dissociation, sedation, and elevated blood pressure, which are related to peak plasma concentrations of ketamine and esketamine. Because ketamine and esketamine have extensive first-pass enterohepatic metabolism, these drugs are typically administered via rapid (40 minutes) intravenous and intranasal routes of administration. Additionally, the metabolites noresketamine / noresketamine and their hydroxyl metabolites are thought to play an important role in ketamine / esketamine antidepressant activity.

[0070] Oral dosage forms of esketamine in a modified-release tablet formulation can improve the safety and tolerability of ketamine therapy while maintaining antidepressant activity. Controlled release of esketamine also slows the absorption and clearance of the drug.

[0071] The ketamine prodrug provided by the present disclosure is an esketamine / promoiety conjugate designed for oral absorption, improved bioavailability, and formulation into a modified-release tablet that releases the ketamine prodrug without producing a high Cmax and is capable of releasing the drug over a sustained period of approximately 12 hours.

[0072] Ketamine is currently used to treat acute pain, chronic pain, major depression, bipolar disorder, and suicidal behavior, as well as an anti-inflammatory agent. Ketamine has low oral bioavailability. The ketamine derivatives provided by the present disclosure are acyloxyalkyl prodrugs of ketamine. Ketamine acyloxyalkyl prodrugs exhibit improved oral ketamine bioavailability compared to ketamine. In the ketamine prodrug, a promoiety is attached to an amide group. In the patient's systemic circulation, the acyloxyalkyl promoiety is cleaved to release ketamine in the systemic circulation. Ketamine, 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, has the following structure: [ka] Both the (S) and (R) isomers are pharmacologically active. (S)-ketamine and (R)-ketamine have the following structures: [ka]

[0073] Ketamine has an oral bioavailability (%F) of approximately 20% in humans. The ketamine derivatives provided by the present disclosure exhibit greater oral bioavailability (%F) of ketamine than orally administered ketamine and exhibit improved pharmacokinetic profiles. Ketamine prodrugs can be used in controlled- and modified-release oral dosage forms.

[0074] Following oral administration, ketamine derivatives can provide therapeutically effective amounts of ketamine in a patient's systemic circulation. For example, metabolites of ketamine, such as (S)-norketamine (noresketamine), (R)-norketamine (norketamine), (2S,6S)-hydroxynorketamine, and (2R,6R)-hydroxynorketamine, are believed to be therapeutically effective in treating certain diseases.

[0075] The compounds provided by the present disclosure are prodrugs of ketamine. For example, compound 39 ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate contains esketamine, which is conjugated to N,N-dimethyl-L-valine (DMV) to form a prodrug that releases esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, and an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activator in the systemic circulation. Preclinical studies have shown that compound 39 is metabolized by CYP2D6, CYP2C19, and CYP3A4 to release esketamine. Compound 1 is being developed for the treatment of major depressive disorder and chronic pain. After oral administration, compound 39 is cleaved into one molar equivalent of esketamine, the active moiety, and DMV.

[0076] Compound 39 and other ketamine prodrugs provided by the present disclosure can be formulated into a modified-release oral tablet to eliminate the concentration-related side effects of dissociation, sedation, and hypertension by lowering the Cmax compared to intranasal SPRAVATO® and intravenously administered ketamine, while delivering doses of esketamine similar to or greater than those known to exhibit antidepressant activity.

[0077] In preclinical pharmacokinetic studies, compound 39 demonstrated rapid absorption and conversion to esketamine in mice, rats, dogs, and monkeys. Systemic exposure, expressed as AUC, was in the proportional subdose to supradose range for compound 39, esketamine, and noresketamine. Preclinical pharmacokinetics of compound 39 suggests that the drug is orally absorbed and that esketamine is rapidly released. No accumulation of compound 39 or its metabolites was observed after repeated administration.

[0078] Ketamine derivatives have the structure of formula (1): [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen and C 1-6 alkyl, R 2 may be selected from a moiety of formula (2), a moiety of formula (3), a moiety of formula (4), and a moiety of formula (5); [ka] During the ceremony, R 3 is hydrogen, C 1-6 Alkyl, and C 7-12 arylalkyl; R 4 is hydrogen and C 1-6 alkyl, R5 is hydrogen, C 1-6 alkyl, —C(═O)—R10, and —C(═O)—O—R10, wherein R 10 is C 1-6 Alkyl, and C 3-6 cycloalkyl; R 6 is C 1-6 Alkyl, C 1-6 alkoxy, and —CF3; n can be an integer from 0 to 3; R7 is hydrogen, C 1-6 Alkyl, -C(=O)-R11, and -C(=O)-OR 10 is selected from: R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl; R 11 -NH2, -CF3, C 1-6 Alkyl, and C 3-6 cycloalkyl; R 9is hydrogen and C 1-3 alkyl.

[0079] In the compound of formula (1), R 1 The carbon atom to which is attached may be in the (S) configuration.

[0080] In the compound of formula (1), R 1 The carbon atom to which is attached may be in the (R) configuration.

[0081] In the compound of formula (1), R 1 can be hydrogen.

[0082] In the compound of formula (1), R 1 may be selected from methyl, ethyl, n-propyl, and iso-propyl.

[0083] In the compound of formula (1), R 2 can be a moiety having the structure of formula (2).

[0084] In the part of formula (2), R 3 can be hydrogen.

[0085] In the part of formula (2), R 3 is C 1-6 It can be alkyl.

[0086] In the part of formula (2), R 3 may be selected from methyl, ethyl, n-propyl, isopropyl, isobutyl, and 2-methylpropyl.

[0087] In the part of formula (2), R 3 is C 7-12 It may be arylalkyl.

[0088] In the part of formula (2), R 3 may be selected from benzyl and phenethyl.

[0089] In the part of formula (2), R3 The carbon atom to which is attached may be in the (S) configuration.

[0090] In the part of formula (2), R 3 The carbon atom to which is attached may be in the (R) configuration.

[0091] In the part of formula (2), R 4 can be hydrogen.

[0092] In the part of formula (2), R 4 is C 1-6 It can be alkyl.

[0093] In the part of formula (2), R 4 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0094] In the part of formula (2), R 5 is C 1-6 It can be alkyl.

[0095] In the part of formula (2), R 5 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0096] In the part of formula (2), R 5 can be hydrogen.

[0097] In the portion of formula (2), R5 can be —C(═O)—R10, and R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl.

[0098] In the portion of formula (2), R5 can be —C(═O)—R10, and R 10 can be —CF3.

[0099] In the portion of formula (2), R5 can be —C(═O)—R10, and R 10 is C 1-6 It can be alkyl.

[0100] In the portion of formula (2), R5 can be —C(═O)—R10, and R 10 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0101] In the portion of formula (2), R5 can be —C(═O)—R10, and R 10 is C 3-6 It may be cycloalkyl.

[0102] In the portion of formula (2), R5 can be —C(═O)—R10, and R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl.

[0103] In the portion of formula (2), R5 can be -C(=O)-O-R10, and R 10 is C 1-6 It can be alkyl.

[0104] In the portion of formula (2), R5 can be -C(=O)-O-R10, and R 10 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0105] In the portion of formula (2), R5 can be -C(=O)-O-R10, and R 10 is C 3-6 It may be cycloalkyl.

[0106] In the portion of formula (2), R5 can be -C(=O)-O-R10, and R 10 can be —CF3.

[0107] In the portion of formula (2), R4 can be hydrogen, and R 5 is C 1-6 It can be alkyl.

[0108] In the formula (2), R4 is C 1-6 R may be alkyl;5 is C 1-6 It can be alkyl.

[0109] In the moiety of formula (2), R4 can be hydrogen and R5 can be -C(=O)-R 10 It could be.

[0110] In the formula (2), R4 is C 1-6 alkyl, and R5 is -C(=O)-R 10 It could be.

[0111] In the moiety of formula (2), R4 can be hydrogen and R5 can be -C(=O)-OR 10 It could be.

[0112] In the formula (2), R4 is C 1-6 alkyl, and R5 is -C(=O)-OR 10 It could be.

[0113] In the compound of formula (1), R 2 can be a moiety having the structure of formula (3):

[0114] In the part of equation (3), R 6 is C 1-6 It can be alkyl.

[0115] In the part of equation (3), R 6 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0116] In the part of equation (3), R 6 is C 1-6 It may be alkoxy.

[0117] In the part of equation (3), R 6 may be selected from methoxy, ethoxy, n-propoxy, and isopropoxy.

[0118] In the compound of formula (1), R 2can be a moiety having the structure of formula (4).

[0119] In the portion of formula (4), n can be 0, 1, 2, or 3.

[0120] In the part of formula (4), n can be 0.

[0121] In the part of formula (4), n can be 1.

[0122] In the part of equation (4), R 9 can be hydrogen.

[0123] In the part of equation (4), R 9 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0124] In the compound of formula (1), R 2 can be a moiety having the structure of formula (5).

[0125] In the part of equation (5), R 2 can be piperidin-2-yl, piperidin-3-yl, and piperidin-4-yl.

[0126] In the part of equation (5), R 7 can be hydrogen.

[0127] In the part of equation (5), R 7 is C 1-6 It can be alkyl.

[0128] In the portion of formula (5), R7 can be -C(=O)-R11, and R 11 is -NH2, C 1-6 Alkyl, and C 3-6 cycloalkyl.

[0129] In the portion of formula (5), R7 can be -C(=O)-R11, and R 11 can be —NH2.

[0130] In the portion of formula (5), R7 can be -C(=O)-R11, and R 11 is C 1-6 It can be alkyl.

[0131] In the portion of formula (5), R7 can be -C(=O)-R11, and R 11 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0132] In the portion of formula (5), R7 can be -C(=O)-R11, and R 11 is C 3-6 It may be cycloalkyl.

[0133] In the portion of formula (5), R7 can be -C(=O)-O-R10, and R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl.

[0134] In the portion of formula (5), R7 can be -C(=O)-O-R10, and R 10 is C 1-6 It can be alkyl.

[0135] In the portion of formula (5), R7 can be -C(=O)-O-R10, and R 10 may be selected from methyl, ethyl, n-propyl, and isopropyl.

[0136] In the portion of formula (5), R7 can be -C(=O)-O-R10, and R 10 is C 3-6 It may be cycloalkyl.

[0137] The compound of formula (1) may be the (R) isomer and may have the structure of formula (1a): [ka]

[0138] The compound of formula (1) may be the (S) isomer and may have the structure of formula (1b): [ka]

[0139] The compounds of formula (1), (1a), and (1b) may be free bases.

[0140] The compound of formula (1), the compound of formula (1a), and the compound of formula (1b) may be a pharmaceutically acceptable salt, for example, the compound of formula (1), the compound of formula (1a), and the compound of formula (1b) may be a hydrochloride salt.

[0141] The compound of formula (1) can be a pharmaceutically acceptable salt of a compound of formula (1), a hydrate thereof, or a solvate of any of the foregoing.

[0142] The compound of formula (1) 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl(tert-butoxycarbonyl)glycinate (4), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl(tert-butoxycarbonyl)-L-valinate (5), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alaninate (7), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-valinate (8), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl-1-methylpiperidine-4-carboxylate (17), 1-(2-(isobutyramido)acetoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (19), (2-(3-methyloxetan-3-yl)acetoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (22), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)propyl 2-(3-methyloxetan-3-yl)acetate (24), 1-(2-(3-methyloxetan-3-yl)acetoyloxy)-2-methylpropyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (26), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)propylacetylglycinate (27), 1-(2-acetamidoacetoyloxy)-2-methylpropyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (28), (2-acetamidoacetyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (31), ((S)-2-acetamido-3-methylbutanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (32), ((S)-2-acetamidopropanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (33), (2-(isobutyramido)acetoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (34), ((S)-2-(isobutyramido)propanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (35), ((S)-2-(isobutyramido)-3-methylbutanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (36), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl L-valinate (37), (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl glycinate (38), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39), (2-(N-methylacetamido)acetoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (40), 1-(2-(N-methylacetamido)acetoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (41), 1-(2-(propionamido)acetoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (42), (2-(propionamido)acetoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (43), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl L-alaninate (44), 1-(2-(propionamido)acetoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (45), (2-(2,2,2-trifluoroacetamido)acetoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (46), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl dimethyl-L-alaninate (47), ((S)-2-(2,2,2-trifluoroacetamido)-3-methylbutanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (48), 1-(2-(2,2,2-trifluoroacetamido)acetoyloxy)propyl(S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (49), ((S)-2-(2,2,2-trifluoroacetamido)propanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (50), 1-(2-(2,2,2-trifluoroacetamido)acetoyloxy)-2-methylpropyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (51), 1-((S)-2-(2,2,2-trifluoroacetamido)-3-methylbutanoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (52), 1-((S)-2-(2,2,2-trifluoroacetamido)propanoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (53), 1-((S)-2-acetamido-4-methylpentanoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (57), ((S)-2-acetamido-4-methylpentanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (58), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (59), ((2S,3R)-2-acetamido-3-methylpentanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (60), 1-(2-acetamidoacetoyloxy)ethyl (R)-1-(2-chlorophenyl)-2-oxocyclohexyl-methylcarbamate (62), 1-(2-(3-methyloxetan-3-yl)acetoyloxy)ethyl (R)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (63), 1-((S)-2-acetamidopropanoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (64), 1-((S)-2-acetamido-3-methylbutanoyloxy)ethyl (R)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (65), (2-(3-methyloxetan-3-yl)acetoyloxy)methyl (R)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (66), (2-acetamidoacetyloxy)methyl 1-(2-chlorophenyl)-2-oxocyclohexyl-methylcarbamate (68), ((S)-2-acetamido-3-methylbutanoyloxy)methyl 1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (69), ((S)-2-acetamidopropanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (70), ((S)-2-acetamido-4-methylpentanoyloxy)methyl (R)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (71), ((2S,3R)-2-acetamido-3-methylpentanoyloxy)methyl 1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (72), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-isoleucinate hydrochloride (74), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl methyl-L-valinate hydrochloride (75), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-leucinate hydrochloride (76), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldiethyl-L-valinate hydrochloride (77), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl methyl-L-alaninate 2,2,2-trifluoroacetic acid (78), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dipropyl-L-valinate (79), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl L-leucinate hydrochloride (80), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl isopropyl-L-valinate hydrochloride (81), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methylpropyl-L-valinate hydrochloride (82), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methylethyl-L-valinate (83), (Piperidine-4-carboxyloyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (86), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methylacetyl-D-propionate (87), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methylacetyl-L-phenylalaninate (88), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methylacetyl-L-tyrosinate (89), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl dimethyl-L-valinate (90), and It may be selected from pharmaceutically acceptable salts of any of the foregoing.

[0143] The compound of formula (1) can be 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-aminonicotinate.

[0144] The compound of formula (1) 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alaninate (7), 1-(isonicotinoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (18), 1-(2-(isobutyramido)acetoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (19), (2-(3-methyloxetan-3-yl)acetoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (22), 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)propylacetylglycinate (27), 1-(2-acetamidoacetoyloxy)-2-methylpropyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (28), ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39), ((2S,3R)-2-acetamido-3-methylpentanoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (60), and It may be selected from pharmaceutically acceptable salts of any of the foregoing.

[0145] Compounds provided by the present disclosure have the structure of formula (1): [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen and C 1-6 alkyl, R 2 may be selected from the portion of formula (6): [ka] During the ceremony, p is an integer from 1 to 3, Each R 8 are independently hydrogen, C 1-6 alkyl, and -NH2.

[0146] In compounds of formula (1) where R2 is a moiety of formula (6), R 1The carbon atom to which is attached may be in the (S) configuration.

[0147] In compounds of formula (1) where R2 is a moiety of formula (6), R 1 The carbon atom to which is attached may be in the (R) configuration.

[0148] In compounds of formula (1) where R2 is a moiety of formula (6), R 1 can be hydrogen.

[0149] In compounds of formula (1) where R2 is a moiety of formula (6), R 1 is C 1-6 It can be alkyl.

[0150] In compounds of formula (1) where R2 is a moiety of formula (6), R 1 may be selected from methyl, ethyl, propyl, and isopropyl.

[0151] In part of formula (6), p can be 1.

[0152] In the part of formula (6), p can be 2.

[0153] In the part of formula (6), p can be 3.

[0154] In the part of formula (6), each R 8 can be hydrogen.

[0155] In the part of formula (6), each R 8 independently, C 1-6 It can be alkyl.

[0156] In the part of formula (6), each R 8 may be independently selected from methyl, ethyl, propyl, and isopropyl.

[0157] In the part of formula (6), each R 8 can independently be —NH 2 .

[0158] R 2 In compounds of formula (1) where is a moiety of formula (6), the compound is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl nicotinate (14), 1-(isonicotinoyloxy)ethyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (18), (Nicotinoyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (29), (4-methylpyridine-3-carboxyloyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (54), (2-methylpyridine-3-carboxyloyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (55), (6-methylpyridine-3-carboxyloyloxy)methyl (S)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (56), (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-aminonicotinate (61), (Nicotinoyloxy)methyl (R)-1-(2-chlorophenyl)-2-oxocyclohexylmethylcarbamate (67), (R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-aminonicotinate (73), and It may be selected from pharmaceutically acceptable salts of any of the foregoing.

[0159] R 2 In compounds of formula (1) where is a moiety of formula (6), the compound may be an (R)-isomer having the structure of formula (1a): [ka]

[0160] R 2 In compounds of formula (1) where is a moiety of formula (6), the compound may be an (S)-isomer having the structure of formula (1b): [ka]

[0161] R 2 In compounds of formula (1) where is a moiety of formula (6), the compound may include a hydrochloride salt.

[0162] Compounds of formula (1) may have the structure of subgenus (2A), wherein: R 1 may be selected from hydrogen and methyl; R 2 may be part of equation (2), R 3 is hydrogen and C 1-4 alkyl, R 4 is hydrogen and C 1-3 alkyl, R5 is C 1-3 alkyl and —C(═O)—R 10 , where R 10 is C 1-3 It may be selected from alkyl.

[0163] In compounds of subgenus (2A), R 1 can be hydrogen.

[0164] In compounds of subgenus (2A), R 1 can be methyl.

[0165] In compounds of subgenus (2A), R 1 The carbon atom to which is attached may be in the (S) configuration.

[0166] In compounds of subgenus (2A), R 1 The carbon atom to which is attached may be in the ® configuration.

[0167] In compounds of subgenus (2A), R 3 can be hydrogen.

[0168] In compounds of subgenus (2A), R 3 is C 1-3 It can be alkyl.

[0169] In compounds of subgenus (2A), R 3 The carbon atom to which is attached may be in the (S) configuration.

[0170] In compounds of subgenus (2A), R 3 The carbon atom to which is attached may be in the t(R) configuration.

[0171] In compounds of subgenus (2A), R 4 can be hydrogen.

[0172] In compounds of subgenus (2A), R 4 is C 1-3 It can be alkyl.

[0173] In compounds of subgenus (2A), R 5 is C 1-3 It can be alkyl.

[0174] In compounds of subgenus (2A), R5 is -C(=O)-R 10 It could be.

[0175] Compounds of formula (1) may have the structure of subgenus (4A), wherein: R 1 may be selected from hydrogen and methyl; R 2 may be part of equation (4), n may be 1, R 9 is C 1-3 It may be selected from alkyl.

[0176] In the compounds of subgenus (4A), R 1can be hydrogen.

[0177] In the compounds of subgenus (4A), R 1 can be methyl.

[0178] In the compounds of subgenus (4A), R 1 The carbon atom to which is attached may be in the (S) configuration.

[0179] In the compounds of subgenus (4A), R 1 The carbon atom to which is attached may be in the (R) configuration.

[0180] In the compounds of subgenus (4A), R 3 can be hydrogen.

[0181] In the compounds of subgenus (4A), R 3 can be methyl.

[0182] Compounds of formula (1) may have the structure of subgenus (5A), wherein: R 1 may be selected from hydrogen and methyl; R 2 may be part of equation (5), R 7 is C 1-3 It may be selected from alkyl.

[0183] In compounds of subgenus (5A), R 1 can be hydrogen.

[0184] In compounds of subgenus (5A), R 1 can be methyl.

[0185] In compounds of subgenus (5A), R 1 The carbon atom to which is attached may be in the (S) configuration.

[0186] In compounds of subgenus (5A), R 1 The carbon atom to which is attached may be in the (R) configuration.

[0187] In compounds of subgenus (5A), R 7 can be methyl.

[0188] Compounds of formula (1) may have the structure of subgenus (6A), wherein: R 1 may be selected from hydrogen and methyl; R 2 may be part of equation (6), R 8 is selected from -NH2.

[0189] In the compounds of subgenus (6A), R 1 can be hydrogen.

[0190] In the compounds of subgenus (6A), R 1 can be methyl.

[0191] In the compounds of subgenus (6A), R 1 The carbon atom to which is attached may be in the (S) configuration.

[0192] In the compounds of subgenus (6A), R 1 The carbon atom to which is attached may be in the (R) configuration.

[0193] The compound of formula (1) may exhibit an oral ketamine bioavailability (%F) of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least 60%. The compound of formula (1) may provide, for example, an oral ketamine bioavailability of 5% to 90%, 10% to 80%, 15% to 70%, or 20% to 60%.

[0194] The compound of formula (1) or a pharmaceutically acceptable salt thereof may have a higher solubility in a 0.1 N hydrochloride solution than in a 50 mM acetate buffer at pH 4.5.

[0195] The ketamine derivative is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39): [ka] or a pharmaceutically acceptable salt thereof.

[0196] The ketamine derivative of formula (39) can be a hydrochloride salt.

[0197] The ketamine derivative of formula (39) can be a free base.

[0198] The compounds of formula (1) are 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3) and 1-(((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (62). [ka] [ka] or a pharmaceutically acceptable salt thereof.

[0199] The compounds of formula (1) are 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6) and 1-(((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (63): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0200] The compounds of formula (1) are (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (22) and R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (66): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0201] The compounds of formula (1) are ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39) and (((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (65). [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0202] The compounds of formula (1) are 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (57) and 1-(((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (71). [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0203] The compounds of formula (1) are 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (58) and 1-(((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (72). [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0204] Methods for synthesizing ketamine derivatives of formula (1) are disclosed in U.S. Application Publication No. 2020 / 0231540A1, which is incorporated by reference in its entirety.

[0205] The uncoated granules may comprise a ketamine derivative of formula (1) and a granule binder.

[0206] The uncoated granules can contain, for example, 95.0% to 99.5% by weight of the compound of Formula (1) or a pharmaceutically acceptable salt thereof, 95.5% to 99.0% by weight, 96.0% to 98.5% by weight, or 96.5% to 98.0% by weight of the compound of Formula (1) or a pharmaceutically acceptable salt thereof, where the weight percentages are based on the total weight of the uncoated granules. The uncoated granules can contain, for example, more than 95% by weight of the compound of Formula (1) or a pharmaceutically acceptable salt thereof, for example, more than 96%, more than 97%, more than 98%, or more than 99% by weight of the compound of Formula (1) or a pharmaceutically acceptable salt thereof, where the weight percentages are based on the total weight of the uncoated granules.

[0207] The uncoated granules may include a granule binder or a combination of granule binders.

[0208] Examples of suitable granule binders include polyvinylpyrrolidone, copovidone carbomer, corn starch, pregelatinized starch, carboxymethylcellulose, hydroxypropyl methylcellulose, polyethylene glycol, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, calcium carboxymethylcellulose, guar galactomannan, ethylcellulose, chitosan hydrochloride, dextrin, hydroxypropyl starch, ceratonia, inulin, magnesium aluminum silicate, maltodextrin, methylcellulose, dextrates, polyethylene oxide, povidone, sodium alginate, starch, liquid glucose, sucrose, compression sugar, zein, gelatin, polymethacrylate, sorbitol, glucose, sodium alginate, acacia, and combinations of any of the foregoing.

[0209] Examples of suitable granule binders include hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, or a combination of any of the foregoing.

[0210] The granule binder may include hydroxypropyl methylcellulose. The hydroxypropyl methylcellulose binder may have, for example, a viscosity of 2.4 mPa-sec to 3.6 mPa-sec, a 2910 substitution type, a 28% to 30% methoxy content, and a 7% to 12% hydroxypropyl content. The granule binder may include hydroxypropyl methylcellulose E3. Hydroxypropyl methylcellulose E3 is characterized as a 2910 substitution type and a viscosity of 3 mPa-sec in a 2% by weight aqueous solution at 20°C. An example of hydroxypropyl methylcellulose E3 is Pharmacoat® 603, available from Shin-Etsu Chemical Co., Ltd.

[0211] The uncoated granules can contain, for example, 0.5% to 5% by weight of granule binder, 1% to 4% by weight, or 1.5% to 3.5% by weight of granule binder, where the weight percentages are based on the total weight of the uncoated granules. The uncoated granules can contain, for example, less than 5% by weight of granule binder, less than 4% by weight, less than 3% by weight, less than 2% by weight, or less than 1% by weight of granule binder, where the weight percentages are based on the total weight of the uncoated granules.

[0212] The uncoated granules can contain, for example, 97% to 99% by weight of the compound of formula (1) or a pharmaceutically acceptable salt thereof, and 1% to 3% by weight of a granule binder, the weight percentages being based on the total weight of the uncoated granules.

[0213] The uncoated granules can have an average diameter of, for example, 100 μm to 500 μm, 150 μm to 400 μm, or 200 μm to 300 μm, where the average diameter is determined by laser diffraction or sieve analysis.

[0214] The pharmaceutical compositions provided by the present disclosure can contain, for example, 35% to 55% by weight of uncoated granules, or 40% to 50% by weight of uncoated granules, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0215] Pharmaceutical compositions provided by the present disclosure can include, for example, more than 35% by weight of uncoated granules, more than 40% by weight, or more than 50% by weight of uncoated granules, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0216] Pharmaceutical compositions provided by the present disclosure can include, for example, less than 50% by weight of uncoated granules, less than 45% by weight, or less than 40% by weight of uncoated granules, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0217] The uncoated granules can contain, for example, less than 1.0 wt. % water, less than 0.75 wt. % water, less than 0.5 wt. % water, less than 0.25 wt. % water, or less than 0.1 wt. % water, where the weight percentage is based on the total weight of the granules. The wet granules can contain, for example, 0.01 wt. % to 1.0 wt. % water, 0.1 wt. % to 0.75 wt. % water, or 0.1 wt. % to 0.5 wt. % water, or 0.1 wt. % to 0.4 wt. % water, where the weight percentage is based on the total weight of the uncoated granules.

[0218] Uncoated granules can be prepared, for example, by (a) granulating a dry mixture of the ingredients to obtain a dry granulation, and (b) adding a solvent, such as, for example, water, ethanol, isopropanol, and / or acetone, to the dry granulation and granulating to obtain a wet granulation.

[0219] Dry blending the dry mixture can include, for example, granulating at a mixer speed of 700 rpm to 1000 rpm, e.g., 800 rpm to 900 rpm, and a chopper speed of, e.g., 3,000 rpm to 4,200 rpm, e.g., 3,200 rpm to 4,000 rpm, or 3,400 rpm to 3,800 rpm, for a period of, e.g., 5 minutes to 20 minutes, e.g., 5 minutes to 15 minutes, or 5 minutes to 10 minutes.

[0220] The dry blend obtained in step (a) can be wet granulated.

[0221] During wet granulation, water can be added to the dry granulation at a rate of, for example, 0.0025 wt% / min to 0.0075 wt% / min, where wt% is based on the total weight of the dry mixture. The wet granulation can be granulated for, for example, 5 to 20 minutes, for example, 5 to 15 minutes, or 5 to 10 minutes. During wet granulation, the mixer speed can be, for example, 700 rpm to 1000 rpm, for example, 800 rpm to 900 rpm, and the chopper speed can be, for example, 3,000 rpm to 4,200 rpm, for example, 3,200 rpm to 4,000 rpm, or 3,400 rpm to 3,800 rpm.

[0222] At the end of the process, the wet granulation can contain, for example, 3% to 15% by weight water, e.g., 3% to 12% by weight, 3% to 8% by weight, 3.5% to 6.5% by weight, or 4% to 6% by weight water, where the weight percentages are based on the total weight of the wet granulation.

[0223] The amount of water added is determined by weighing the amount of water incorporated into / consumed by the dry mix.

[0224] During the wet granulation, the temperature of the wet granulated product can be maintained at, for example, 20°C to 25°C.

[0225] The wet granulation can then be wet massed to form smooth, dense granules.

[0226] Wet massing can be carried out, for example, at a mixer speed of 400 rpm to 700 rpm, e.g., 500 rpm to 600 rpm, and a chopper speed of, for example, 1,300 rpm to 2,300 rpm, e.g., 1,500 rpm to 2,100 rpm, for 20 minutes to 100 minutes, e.g., 30 minutes to 90 minutes, 30 minutes to 80 minutes, or 30 minutes to 60 minutes.

[0227] During wet massing, the temperature of the wet granulation can be maintained, for example, at a temperature of from 20° C. to 25° C., such as from 22° C. to 25° C. The temperature of the granulation can be maintained, for example, by immersing the mixing bowl containing the granulation in a temperature-controlled bath.

[0228] Wet massing can be carried out, for example, using a granulator bowl at a temperature of 22°C to 24°C, a mixer speed of 525 rpm to 575 rpm, and a chopper speed of 1700 rpm to 1900 rpm for 20 minutes to 80 minutes, e.g., 25 minutes to 70 minutes, 30 minutes to 60 minutes, or 35 minutes to 55 minutes.

[0229] During wet massing, the wet granulation can contain, for example, 1 wt % to 15 wt % water, 2 wt % to 12 wt %, 4 wt % to 10 wt %, or 4 wt % to 8 wt % water, where the wt % is based on the total weight of the wet granulation.

[0230] After wet massing, the wet granulation can be dried.

[0231] The wet granulation can be dried in an oven or fluid bed dryer until the loss on drying (LOD) or Karl Fischer analysis is, for example, less than 1.0% w / w.

[0232] The uncoated granules provided by the present disclosure do not include a coating.

[0233] Granules provided by the present disclosure, referred to as coated granules, can include one or more coatings.

[0234] The coating can have an average thickness of, for example, less than 300 μm, less than 200 μm, less than 150 μm, less than 100 μm, less than 50 μm, or less than 25 μm.

[0235] The coated granules can contain, for example, less than 50% by weight, less than 40% by weight, less than 30% by weight, less than 20% by weight, or less than 10% by weight of coating, where the weight percentage is based on the total weight of the coated granules.

[0236] Dosage forms containing highly water-soluble active pharmaceutical ingredients can benefit from having a coating to reduce the release rate of the active pharmaceutical ingredient and / or increase the stability of the active pharmaceutical ingredient by minimizing moisture ingress.

[0237] The coating may comprise a pharmaceutically acceptable polymer, a plasticizer, an anti-tack agent, a colorant or pigment, a glidant, a viscosity modifier, or a combination of any of the foregoing.

[0238] For example, the coating can include an immediate release coating or a controlled release coating. The controlled release coating can include, for example, a delayed release coating, a pH release coating, a sustained release coating, or a modified release coating. Delayed release drug delivery systems are designed to deliver a drug at a specific time or over a period of time after administration.

[0239] The coating may include a water-soluble coating and may include polymers such as polyvinyl alcohol, hydroxypropyl methylcellulose, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl ethyl cellulose, polyethylene glycol, hydroxyethyl cellulose, and combinations of any of the foregoing.

[0240] The coating may comprise a water-insoluble or water-resistant coating to protect the dosage form from absorbing water during storage. Examples of suitable water-insoluble or water-resistant coatings may include polymers such as ethyl cellulose, polyacrylates, polymethacrylates, and combinations of any of the foregoing.

[0241] The coating can provide, for example, time-dependent release, pH-dependent release, or sustained release.

[0242] The coating can be applied to the granules provided by the present disclosure by any suitable method, such as spraying a solution, suspension, or dispersion of the coating onto the granules in a fluidized bed apparatus.

[0243] The coatings provided by the present disclosure may include a controlled release polymer or a combination of controlled release polymers.

[0244] Examples of suitable controlled release polymers include carbomer copolymer, shellac, carbomer homopolymer, hypromellose (hydroxypropyl methylcellulose) polymer, carbomer interpolymer, sodium carboxymethylcellulose, carrageenan, cerabrate, ethylcellulose, glyceryl monooleate, pregelatinized modified starch, glyceryl monostearate, guar gum, hydroxypropyl betadex, hydroxypropyl cellulose, polyethylene oxide, polyvinyl acetate dispersion, sodium alginate, pregelatinized starch, xanthan gum, alginic acid, ethyl acrylate / methyl methacrylate copolymer, acrylic acid / allylsucrose polymer, acrylic acid / allylpentaerythritol polymer, acrylic acid / alkyl acrylate / allylpentaerythritol copolymer, and combinations of any of the foregoing.

[0245] The controlled release polymer may include hydroxypropyl methylcellulose.

[0246] Pharmaceutical compositions provided by the present disclosure may include a compound of Formula (1), which may be in the form of uncoated granules comprising the compound of Formula (1) and a granule binder, a controlled release polymer such as a water-soluble polymer, microcrystalline cellulose, a surfactant, and a lubricant.

[0247] The pharmaceutical compositions provided by the present disclosure can comprise, for example, 30% to 60% by weight of uncoated granules, 35% to 55% by weight, or 40% to 50% by weight of uncoated granules, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0248] Pharmaceutical compositions provided by the present disclosure can include, for example, more than 30% by weight of uncoated granules, more than 35% by weight, more than 40% by weight, more than 45% by weight, more than 50% by weight, or more than 55% by weight of uncoated granules, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0249] Pharmaceutical compositions provided by the present disclosure can comprise, for example, less than 60% by weight, less than 55% by weight, less than 50% by weight, less than 45% by weight, less than 40% by weight, or less than 35% by weight of uncoated granules, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0250] The pharmaceutical compositions provided by the present disclosure may include a controlled release polymer or a combination of controlled release polymers.

[0251] The release-controlling polymer can be a water-soluble polymer.

[0252] Examples of suitable water-soluble polymers include hydroxypropyl cellulose, polyvinyl alcohol, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, povidone, copovidone, and poloxamer.

[0253] The water-soluble polymer may include hydroxypropyl methylcellulose or a combination of different hydroxypropyl methylcellulose polymers.

[0254] Hydroxypropyl methylcellulose controlled release polymers may be characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 at 25°C (2% in water), a hydroxypropyl content of 7.5% to 8.5%, and a viscosity of 80 mPa-s (cP) to 120 mPa-s (Brookfield: 2% in water at 20°C).

[0255] Hydroxypropyl methylcellulose controlled release polymers may be characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 at 25°C (2% in water), a hydroxypropyl content of 7.5% to 8.5%, and a viscosity of 2,600 mPa-s (cP) to 5,000 mPa-s (Brookfield: 2% in water at 20°C).

[0256] The hydroxypropyl methylcellulose polymer may be selected from Methocel™ K100 Premium LV DC2, Methocel™ K4M Premium DC2, and combinations thereof. Methocel™ products are available from Colorcon.

[0257] Hydroxypropyl methylcellulose is, for example, 50% to 100% by weight of hydroxypropyl methylcellulose, characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 at 25°C (2% in water), a hydroxypropyl content of 7.5% to 8.5%, and a viscosity of 2,600 mPa-s (cP) to 5,000 mPa-s (Brookfield: 2% in water at 20°C); and 0% to 50% by weight of hydroxypropyl methylcellulose characterized by a 22% to 24% methoxyl content, a pH of 5 to 8 at 25°C (2% in water), a 7.5% to 8.5% hydroxypropyl content, and a viscosity of 2,600 mPa-s (cP) to 5,000 mPa-s (Brookfield: 2% in water at 20°C), The weight percentages are based on the total weight of the hydroxypropyl methylcellulose.

[0258] Hydroxypropyl methylcellulose is, for example, 60% to 100% by weight of hydroxypropyl methylcellulose, characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 at 25°C (2% in water), a hydroxypropyl content of 7.5% to 8.5%, and a viscosity of 2,600 mPa-s (cP) to 5,000 mPa-s (Brookfield: 2% in water at 20°C); and 0% to 40% by weight of hydroxypropyl methylcellulose characterized by a 22% to 24% methoxyl content, a pH of 5 to 8 at 25°C (2% in water), a 7.5% to 8.5% hydroxypropyl content, and a viscosity of 2,600 mPa-s (cP) to 5,000 mPa-s (Brookfield: 2% in water at 20°C), The weight percentages are based on the total weight of the hydroxypropyl methylcellulose.

[0259] The pharmaceutical compositions provided by the present disclosure can contain, for example, 10% to 60% by weight of a water-soluble polymer such as hydroxypropyl methylcellulose, 10% to 50% by weight, 20% to 40% by weight, 22% to 38% by weight, 24% to 36% by weight, 26% to 34% by weight, or 28% to 32% by weight of a water-soluble polymer such as hydroxypropyl methylcellulose, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0260] Pharmaceutical compositions provided by the present disclosure can include, for example, more than 15% by weight of a water-soluble polymer such as hydroxypropyl methylcellulose, more than 20% by weight, more than 25% by weight, more than 30% by weight, or more than 35% by weight of a water-soluble polymer, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0261] Pharmaceutical compositions provided by the present disclosure can include, for example, less than 60% by weight of a water-soluble polymer such as hydroxypropyl methylcellulose, less than 50% by weight, less than 35% by weight, less than 30% by weight, less than 25% by weight, or less than 20% by weight of a water-soluble polymer, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0262] The pharmaceutical compositions provided by the present disclosure may include a surfactant or a combination of surfactants.

[0263] Suitable surfactants are capable of forming micelles at high pH, ​​such as above pH 4, above pH 5, or above pH 6.

[0264] The surfactant may comprise an anionic surfactant. Examples of suitable anionic surfactants include soap, alkylbenzenesulfonate, alkylsulfonate, alkyl sulfate, salt of fluorinated fatty acid, silicone, fatty alcohol sulfate, polyoxyethylene fatty alcohol ether sulfate, α-olefin sulfonate, polyoxyethylene fatty alcohol phosphate ether, alkyl alcohol amide, alkyl sulfonic acid acetamide, alkyl succinic acid sulfonate, amino alcohol alkylbenzenesulfonate, naphthenate, alkylphenol sulfonate, and polyoxyethylene monolaurate.

[0265] Other examples of suitable anionic surfactants include sodium lauryl sulfate, sodium laureth sulfate, ammonium lauryl sulfate, ammonium laureth sulfate, sodium stearate, potassium cocoate, sodium myristyl sulfate, palmityl sulfate, and disodium lauryl sulfosuccinate.

[0266] The anionic surfactant may include anionic sulfate / sulfonate surfactants.

[0267] Examples of suitable anionic sulfates / surfactants include sodium lauryl sulfate, sodium laureth sulfate, ammonium lauryl sulfate, ammonium laureth sulfate, palmityl sulfate, and disodium lauryl sulfosuccinate.

[0268] Anionic sulfate / sulfonate surfactants may include sodium lauryl sulfate.

[0269] Sodium lauryl sulfate may be characterized by a critical micelle concentration of, for example, 1.5 g / L to 3.0 g / L, such as 1.7 g / L to 2.8 g / L or 1.9 g / L to 2.6 g / L at 20° C., the critical micelle concentration being determined using a force tensiometer.

[0270] Pharmaceutical compositions provided by the present disclosure can contain, for example, 5% to 15% by weight of anionic sulfate / sulfonate surfactant, 7% to 13% by weight, or 9% to 11% by weight of anionic sulfate / sulfonate surfactant, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0271] Pharmaceutical compositions provided by the present disclosure can include, for example, greater than 5 wt. % anionic sulfate / sulfonate surfactant, greater than 7 wt. %, greater than 9 wt. %, greater than 11 wt. %, or greater than 13 wt. % anionic sulfate / sulfonate surfactant, where the wt. % is based on the total weight of the pharmaceutical composition.

[0272] Pharmaceutical compositions provided by the present disclosure can include, for example, less than 15% by weight of anionic sulfate / sulfonate surfactant, less than 13% by weight, less than 11% by weight, less than 9% by weight, or less than 7% by weight of anionic sulfate / sulfonate surfactant, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0273] Pharmaceutical compositions provided by the present disclosure can include, for example, 30% to 60% by weight of uncoated granules, 10% to 60% by weight of a controlled-release polymer, such as a water-soluble polymer, and 5% to 15% by weight of an anionic sulfate / sulfonate surfactant, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0274] Pharmaceutical compositions provided by the present disclosure can include, for example, 35% to 55% by weight of uncoated granules, 15% to 35% by weight of a controlled-release polymer, such as a water-soluble polymer, and 7% to 13% by weight of an anionic sulfate / sulfonate surfactant, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0275] Pharmaceutical compositions provided by the present disclosure can include, for example, 40% to 50% by weight of uncoated granules, 20% to 30% by weight of a controlled-release polymer, such as a water-soluble polymer, and 9% to 11% by weight of an anionic sulfate / sulfonate surfactant, where the weight percentages are based on the total weight of the pharmaceutical composition.

[0276] Pharmaceutical compositions provided by the present disclosure can have a water content of, for example, less than 3 wt%, less than 2.5 wt%, less than 2.0 wt%, less than 1.5 wt%, less than 1.0 wt%, or less than 0.5 wt%, where the weight percentage is based on the total weight of the pharmaceutical composition. Pharmaceutical compositions provided by the present disclosure can have a water content of, for example, 0.1 wt% to 3 wt%, 0.1 wt% to 2 wt%, or 0.1 wt% to 1.0 wt%, where the weight percentage is based on the total weight of the composition.

[0277] The pharmaceutical compositions provided by the present disclosure may include a filler material or combination of fillers.

[0278] Examples of suitable fillers include microcrystalline cellulose, powdered cellulose, anhydrous lactose, lactose monohydrate, spray dried lactose, mannitol, starch, pregelatinized starch, corn starch, corn starch, sorbitol, sucrose, compressible sugar, confectioners' sugar, sugar spheres, dextrates, dextrin, dextrose, calcium phosphate, dibasic, anhydrous, calcium carbonate, maltose, maltodextrin, kaolin, calcium phosphate, dibasic, dihydrate, tribasic calcium phosphate, calcium sulfate, cerabrate, calcium lactate, cellulose acetate, silicified microcrystalline cellulose, cellulose acetate, corn syrup, pregelatinized starch and corn starch, corn syrup, solids, erythritol, ethyl cellulose, ethyl acrylate and methacrylic acid. methyl copolymer dispersion, fructose, isomaltose, alpha-lactalbumin, lactitol, magnesium carbonate, magnesium oxide, methacrylic acid and ethyl acrylate copolymer, methacrylic acid and methyl methacrylate copolymer, polydextrose, sodium chloride, simethicone, pregelatinized modified starch, starch, pea, hydroxypropyl pea starch, starch, pregelatinized hydroxypropyl pea, potato starch, starch, hydroxypropyl potato, pregelatinized hydroxypropyl potato starch, starch, tapioca, wheat starch, starch hydrolysate, hydrogenated, pullulan, talc, methacrylic acid amino copolymer, trehalose, xylitol, and combinations of any of the foregoing.

[0279] The filler may include microcrystalline cellulose.

[0280] The microcrystalline cellulose may have an average particle size of from 80 μm to 120 μm or from 90 μm to 110 μm, for example, as determined using sieve analysis or laser diffraction.

[0281] Microcrystalline cellulose may include, for example, Avicel® PH102.

[0282] Pharmaceutical compositions provided by the present disclosure can include, for example, 5% to 35% by weight of filler, 10% to 30% by weight, 10% to 20% by weight, 25% to 35% by weight, or 15% to 25% by weight of filler, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0283] Pharmaceutical compositions provided by the present disclosure can include, for example, more than 5% by weight of filler, more than 10% by weight, more than 15% by weight, more than 20% by weight, more than 25% by weight, or more than 30% by weight of filler, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0284] Pharmaceutical compositions provided by the present disclosure can include, for example, less than 35% by weight of filler, less than 30% by weight, less than 25% by weight, less than 20% by weight, or less than 15% by weight of filler, where the weight percentage is based on the total weight of the pharmaceutical composition.

[0285] The pharmaceutical compositions provided by the present disclosure may include a lubricant or a combination of lubricants.

[0286] Examples of suitable lubricants include magnesium stearate, magnesium silicate, calcium stearate, sodium lauryl sulfate, sodium stearyl fumarate, magnesium lauryl sulfate, stearic acid, calcium stearate, glyceryl behenate, behenoyl polyoxylglyceride, glyceryl dibehenate, lauric acid, glyceryl monostearate, glyceryl tristearate, myristic acid, palmitic acid, poloxamer, polyethylene glycol, polysorbate, polyoxyl 10 oleyl ether, polyoxyl 15 hydroxystearate, polysorbate, potassium benzoate, sodium benzoate, sorbitan monolaurate, sorbitan monooleate, sodium stearate, sorbitan monopalmitate, sorbitan monostearate, zinc stearate, sorbitan sequiolate, sorbitan trioleate, talc, and combinations of any of the foregoing.

[0287] Lubricants may include magnesium stearate.

[0288] Pharmaceutical compositions provided by the present disclosure can contain, for example, 0.1 wt % to 3.5 wt %, 0.2 wt % to 2.0 wt %, 0.2 wt % to 1.0 wt %, or 0.3 wt % to 0.7 wt % of a lubricant, where the wt % is based on the total weight of the pharmaceutical composition.

[0289] Pharmaceutical compositions provided by the present disclosure can include, for example, more than 0.1 wt. % of a lubricant, more than 0.25 wt. %, more than 0.5 wt. %, or more than 1.0 wt. % of a lubricant, where the wt. % is based on the total weight of the pharmaceutical composition.

[0290] Pharmaceutical compositions provided by the present disclosure can contain, for example, less than 1.5 wt. % of a lubricant, less than 1.0 wt. %, or less than 0.5 wt. % of a lubricant, where the wt. % is based on the total weight of the pharmaceutical composition.

[0291] Pharmaceutical compositions provided by the present disclosure in the form of granules can be prepared as described in the Examples.

[0292] Pharmaceutical compositions provided by the present disclosure in the form of granules may have a bulk density of, for example, 0.45 g / mL to 0.51 g / mL, 0.46 g / mL to 0.50 g / mL, or 0.47 g / mL to 0.49 g / mL, where the bulk density is determined using a bulk density cylinder.

[0293] The pharmaceutical composition provided by the present disclosure in the form of a granule may have an angle of repose of, for example, 35 degrees to 45 degrees, 36 degrees to 44 degrees, or 38 degrees to 42 degrees.

[0294] Pharmaceutical compositions provided by the present disclosure in the form of granules can have an inherent flowability value of, for example, 7 to 14, 8 to 13, or 9 to 12, and the inherent flowability value is determined according to the USP <1174> is determined using a Flodex™ instrument according to

[0295] Pharmaceutical compositions provided by the present disclosure may include a diluent, a disintegrant, a glidant, a colorant, a flavoring agent, a sweetener, a release-modifying agent, or a combination of any of the foregoing.

[0296] Oral dosage forms provided by the present disclosure can include the pharmaceutical compositions provided by the present disclosure. Examples of suitable oral dosage forms include tablets, lozenges, capsules, sachets, solutions, and suspensions.

[0297] Oral dosage forms may include, for example, solid oral dosage forms such as tablets.

[0298] Oral dosage forms may include, for example, uncoated tablets, coated tablets, immediate release coated tablets, enteric coated tablets, dispersible tablets, modified release tablets such as sustained release tablets, delayed release tablets, or controlled release tablets, effervescent tablets, lozenges, or sublingual tablets.

[0299] The oral dosage form can provide a therapeutically effective amount of a compound of formula (1) or a metabolite thereof to treat a disease in a patient.

[0300] Oral dosage forms provided by the present disclosure can contain, for example, 1 mg to 100 mg of ketamine equivalent, such as 10 mg to 90 mg, 20 mg to 80 mg, 30 mg to 70 mg, or 40 mg to 60 mg of ketamine equivalent. Oral dosage forms provided by the present disclosure can contain, for example, more than 10 mg of ketamine equivalent, more than 20 mg, more than 40 mg, more than 60 mg, or more than 80 mg of ketamine equivalent. Oral dosage forms provided by the present disclosure can contain, for example, less than 100 mg of ketamine equivalent, less than 80 mg, less than 60 mg, less than 40 mg, or less than 20 mg of ketamine equivalent.

[0301] The oral dosage form can contain, for example, 10 mg to 500 mg of the compound of formula (1), 50 mg to 450 mg, 100 mg to 400 mg, or 150 mg to 350 mg of the compound of formula (1). The oral dosage form can contain, for example, more than 10 mg of the compound of formula (1), more than 50 mg, more than 100 mg, more than 200 mg, more than 300 mg, or more than 400 mg of the compound of formula (1).

[0302] Oral dosage forms can contain, for example, 1 mg to 500 mg equivalents of ketamine, 10 mg to 400 mg equivalents, or 50 mg equivalents to 300 mg equivalents of ketamine. Oral dosage forms can contain, for example, 1 mg to 1,000 mg of the compound of formula (1), 20 mg to 800 mg, or 100 mg to 600 mg of the compound of formula (1).

[0303] Solid oral dosage forms such as tablets can be prepared by compressing the pharmaceutical granulation provided by the present disclosure in a tablet press using, for example, 9 mm tooling, a press speed of 20 RPM, and a compression force of about 28 kN.

[0304] Solid oral dosage forms such as tablets provided by the present disclosure can have a hardness of, for example, 4 kP to 10 kP, 8 kP to 10 kP, or 8.5 kP to 9.5 kP, and hardness is measured according to the USP <1217> (Tablet breaking force) is determined according to the formula:

[0305] Solid oral dosage forms such as tablets provided by the present disclosure can have a thickness of, for example, 5 mm to 10 mm, 6 mm to 9 mm, or 7 mm to 8 mm, and a hardness of, for example, 5 mm to 10 mm, 6 mm to 9 mm, or 7 mm to 8 mm, as measured by the USP <1217> is determined using diameter compression according to

[0306] A solid oral dosage form such as a tablet provided by the present disclosure can have a weight of, for example, 245 mg to 255 mg.

[0307] A solid oral dosage form such as a tablet provided by the present disclosure can have a weight of, for example, less than 0.2, for example, about 0.1, with friability determined using ion sieves.

[0308] The tablets provided by the present disclosure may include an immediate release coating or a seal coating.

[0309] An immediate-release coating refers to a coating that completely dissolves and releases ketamine in, for example, less than 10 minutes, less than 8 minutes, less than 6 minutes, less than 5 minutes, or less than 4 minutes when tested in a USP Type 2 dissolution apparatus in a buffer solution of pH 4.5 at a temperature of 37° C. and a paddle speed of 100 rpm.

[0310] The immediate release coating may comprise a water soluble polymer such as, for example, hydroxypropyl cellulose, polyvinyl alcohol, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, polyvinylpyrrolidone, or polyethylene glycol.

[0311] The solid oral dosage forms, such as tablets, provided by the present disclosure may exhibit a zero order release profile of the compound of Formula (1) or a pharmaceutically acceptable salt thereof over a period of at least 6 hours, at least 8 hours, or at least 10 hours in a two-stage dissolution medium, as determined using a USP I dissolution apparatus at a temperature of 37° C. and an agitation rate of 100 RPM; The first step involves immersing the solid dose in 0.1 N hydrochloric acid for 1 hour; The second step involves immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time.

[0312] The solid oral dosage forms, such as tablets, provided by the present disclosure may be characterized by a dissolution profile of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium, as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 20% to 40% of the compound of formula (1) is released in 2 hours; 30% to 50% of the compound of formula (1) is released in 4 hours, 70% to 80% of the compound of formula (1) is released in 8 hours, 80% to 100% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours, The first step involves immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; the second step involves immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time; The percentages (%) are based on the total amount of the compound of formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form.

[0313] The solid oral dosage forms provided by the present disclosure may be characterized by a dissolution profile of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at a temperature of 37° C. and an agitation speed of 100 RPM: 30% to 40% of the compound of formula (1) is released in 2 hours, 50% to 70% of the compound of formula (1) is released in 4 hours, 70% to 90% of the compound of formula (1) is released in 8 hours, More than 90% of the compound of formula (1) is released in 12 hours; The first step involves immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; the second step involves immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time; The percentages (%) are based on the total amount of the compound of formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form.

[0314] The solid oral dosage forms provided by the present disclosure may be characterized by a dissolution profile of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus with an agitation rate of 100 RPM at a temperature of 37° C.: 15% to 25% of the compound of formula (1) is released in 2 hours; 20% to 35% of the compound of formula (1) is released in 4 hours; 50% to 60% of the compound of formula (1) is released in 8 hours, 70% to 85% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours; The first step involves immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; The second step involves immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period, where the percentage (%) is based on the total amount of the compound of formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form.

[0315] A solid oral dosage form such as a tablet provided by the present disclosure may be characterized by a dissolution profile of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium, as determined using a USP I dissolution apparatus at a temperature of 37°C and an agitation speed of 100 RPM, that is bioequivalent to any one of the dissolution profiles shown in Figure 1, wherein the first stage comprises immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour, and the second stage comprises immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time.

[0316] A solid oral dosage form such as a tablet provided by the present disclosure may be characterized by a dissolution profile of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium, as determined using a USP I dissolution apparatus at a temperature of 37°C and an agitation speed of 100 RPM, that is bioequivalent to any one of the dissolution profiles shown in Figure 1, wherein the first stage comprises immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour, and the second stage comprises immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time.

[0317] Following oral administration of a solid oral dosage form, such as a tablet, provided by the present disclosure to a population of fasted healthy subjects, plasma esketamine concentrations may be bioequivalent as summarized in any one of the pharmacokinetic profiles shown in Figures 4A, 5, 6A, and 7A, and in any one of Tables 8-11.

[0318] Following oral administration of a solid oral dosage form, such as a tablet, provided by the present disclosure to a population of fasted healthy subjects, plasma noresketamine concentrations may be bioequivalent as summarized in any one of the pharmacokinetic profiles shown in Figures 4B, 5, 6B, and 7B, and in any one of Tables 8-11.

[0319] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine concentration C may be, for example, 5 ng / mL to 10 ng / mL, 6 ng / mL to 9 ng / mL, or 6.5 ng / mL to 8.5 ng / mL.

[0320] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma Cmax of noresketamine can be, for example, 40 ng / mL to 80 ng / mL, 45 ng / mL to 75 ng / mL, 50 ng / mL to 70 ng / mL, or 55 ng / mL to 65 ng / mL.

[0321] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine concentration Cmax can be, for example, less than 11 ng / mL, less than 9 ng / mL, less than 7 ng / mL, or less than 5 ng / mL.

[0322] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine concentration Cmax can be, for example, less than 100 ng / mL, less than 80 ng / mL, or less than 60 ng / mL.

[0323] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the Tmax of the mean plasma esketamine concentration can be, for example, 2 to 6 minutes, 2.5 to 5.5 minutes, or 3 to 5 minutes.

[0324] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the Tmax of the mean plasma noresketamine concentration can be, for example, 3 to 6 minutes, 3.5 to 5.5 minutes, or 4 to 5 minutes.

[0325] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the t of the mean plasma esketamine concentration can be, for example, 5 to 15 minutes, 6 to 12 minutes, 7 to 11 minutes, or 8 to 10 minutes.

[0326] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the t of the mean plasma noresketamine concentration can be, for example, 8 to 12 minutes, 8.5 to 11.5 minutes, or 9 to 11 minutes.

[0327] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, from 60 h×ng / mL to 120 h×ng / mL, from 70 h×ng / mL to 110 h×ng / mL, or from 80 h×ng / mL to 100 h×ng / mL.

[0328] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, greater than 50 h×ng / mL, greater than 100 h×ng / mL, greater than 150 h×ng / mL, or greater than 200 h×ng / mL.

[0329] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, 850 h×ng / mL to 1,000 h×ng / mL, 875 h×ng / mL to 975 h×ng / mL, or 850 h×ng / mL to 950 h×ng / mL.

[0330] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, greater than 600 h×ng / mL, greater than 800 h×ng / mL, greater than 1,000 h×ng / mL, or greater than 1,200 h×ng / mL.

[0331] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, 20 hr×ng / mL to 40 hr×ng / mL, 2238 hr×ng / mL to 38 hr×ng / mL, 24 hr×ng / mL to 36 hr×ng / mL, or 26 hr×ng / mL to 34 hr×ng / mL.

[0332] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, greater than 20 h × ng / mL, greater than 30 h × ng / mL, greater than 40 h × ng / mL, or greater than 50 h × ng / mL.

[0333] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, 300 h×ng / mL to 500 h×ng / mL, 325 h×ng / mL to 475 h×ng / mL, 350 h×ng / mL to 450 h×ng / mL, or 375 h×ng / mL to 425 h.

[0334] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, greater than 200 h×ng / mL, greater than 300 h×ng / mL, greater than 400 h×ng / mL, or greater than 500 h×ng / mL.

[0335] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine Cmax / Cave (0-12h) can be, for example, 2-4, 2.2-3.8, 2.4-3.6, or 2.6-3.4.

[0336] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine Cmax / Cave (0-12h) can be, for example, 1.5-3, 1.7-2.8, 1.9-2.6, or 2.1-2.4.

[0337] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine Cmax / Cave (0-12 h) can be, for example, less than 4.0, less than 3.5, less than 3.0, or less than 2.5.

[0338] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine Cmax / Cave (0-12h) can be, for example, less than 3.0, less than 2.5, or less than 2.0.

[0339] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine concentration C may be, for example, 5 ng / mL to 35 ng / mL, 10 ng / mL to 30 ng / mL, or 15 ng / mL to 25 ng / mL.

[0340] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine concentration Cmax is, for example, 50 ng / mL to 300 ng / mL, 100 ng / mL to 250 ng / mL, or 100 ng / mL to 200 ng / mL.

[0341] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine concentration Cmax can be, for example, less than 50 ng / mL, less than 40 ng / mL, less than 35 ng / mL, less than 30 ng / mL, less than 25 ng / mL, less than 20 ng / mL, or less than 15 ng / mL.

[0342] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine concentration Cmax is, for example, less than 350 ng / mL, less than 300 ng / mL, less than 250 ng / mL, less than 200 ng / mL, less than 150 ng / mL, less than 100, or less than 50 ng / mL.

[0343] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the Tmax of the mean plasma esketamine concentration can be, for example, 2 minutes to 5 minutes, 2.5 minutes to 5.0 minutes, or 3.0 minutes to 4.0 minutes.

[0344] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the Tmax of the mean plasma noresketamine concentration can be, for example, 3 minutes to 8 minutes, 3.0 minutes to 7.0 minutes, or 3.0 minutes to 5.0 minutes.

[0345] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the t of the mean plasma esketamine concentration can be, for example, 7 to 11 minutes, 6 to 10 minutes, or 7 to 9 minutes.

[0346] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the t of the mean plasma noresketamine concentration can be, for example, 5.0 minutes to 12.0 minutes, 6.0 minutes to 11.0 minutes, or 9.0 minutes to 11.0 minutes.

[0347] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, 50 h×ng / mL to 300 h×ng / mL, 100 h×ng / mL to 250 h×ng / mL, or 150 h×ng / mL to 200 h×ng / mL.

[0348] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, greater than 50 h×ng / mL, greater than 100 h×ng / mL, greater than 150 h×ng / mL, greater than 200 h×ng / mL, or greater than 250 h×ng / mL.

[0349] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, 500 h×ng / mL to 3,500 h×ng / mL, 1,000 h×ng / mL to 3,000 h×ng / mL, or 1,500 h×ng / mL to 2,500 h×ng / mL.

[0350] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, greater than 500 h×ng / mL, greater than 1,000 h×ng / mL, greater than 1,500 h×ng / mL, greater than 2,000 h×ng / mL, greater than 2,500 h×ng / mL, greater than 3,000 h×ng / mL, or greater than 3,500 h×ng / mL.

[0351] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, 20 hr×ng / mL to 300 hr×ng / mL, 50 hr×ng / mL to 200 hr×ng / mL, or 100 hr×ng / mL to 150 hr×ng / mL.

[0352] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine AUC can be, for example, greater than 20 h×ng / mL, greater than 50 h×ng / mL, greater than 100 h×ng / mL, greater than 150 h×ng / mL, or greater than 200 h×ng / mL.

[0353] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, 200 h×ng / mL to 2,500 h×ng / mL, 300 h×ng / mL to 2,000 h×ng / mL, or 500 h×ng / mL to 1,500 h×ng / mL.

[0354] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine AUC can be, for example, greater than 200 h, greater than 500 h×ng / mL, greater than 1,000 h×ng / mL, greater than 1,500 h×ng / mL, greater than 2,000 h×ng / mL, or greater than 2,500 h×ng / mL.

[0355] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine Cmax / Cave (0-12 h) can be, for example, 1.0 to 4.0, 1.4 to 3.6, 1.8 to 3.2, or 2.2 to 3.0.

[0356] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine Cmax / Cave (0-12 h) can be, for example, 1.0 to 2.2, 1.2 to 2.0, or 1.4 to 1.8.

[0357] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma esketamine Cmax / Cave (0-12 h) can be, for example, less than 4.0, less than 3.5, less than 3.0, less than 2.5, or less than 2.

[0358] Following oral administration of a solid oral dosage form, such as a tablet, containing 100 mg to 400 mg of a compound of Formula (1) provided by the present disclosure to a population of fasted healthy subjects, the mean plasma noresketamine Cmax / Cave (0-12 h) can be, for example, less than 2.5, less than 2.0, or less than 1.5.

[0359] Oral dosage forms, such as tablet dosage forms, provided by the present disclosure can provide dose-proportional amounts of esketamine and noresketamine in the patient's blood.

[0360] Oral dosage forms, such as tablet dosage forms, provided by the present disclosure can provide a dose-proportional amount of esketamine in a patient's blood, such as 10 hr×ng / mL to 1,000 hr×ng / mL, 20 hr×ng / mL to 800 hr×ng / mL, or 50 hr×ng / mL to 600 hr×ng / mL of esketamine.

[0361] Oral dosage forms, such as tablet dosage forms, provided by the present disclosure can provide a dose-proportional amount of noresketamine in a patient's blood, such as 10 hr×ng / mL to 10,000 hr×ng / mL, 50 hr×ng / mL to 8,000 hr×ng / mL, or 100 hr×ng / mL to 6,000 hr×ng / mL of noresketamine.

[0362] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be used to treat diseases known to be treated by ketamine or determined to be treated by ketamine.

[0363] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be used to treat diseases known or determined to be treated by ketamine and one or more additional therapeutic agents.

[0364] For example, the pharmaceutical compositions and oral dosage forms provided by the present disclosure can be used to treat neurological disorders, psychiatric disorders, or pain.

[0365] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be used to treat neurological disorders, such as neurological disorders of the central nervous system.

[0366] Examples of suitable neurological disorders include Alzheimer's disease, amyotrophic lateral sclerosis, low back pain, Bell's palsy, birth defects of the brain and spinal cord, cerebral aneurysms, brain injuries, brain tumors, cerebral palsy, chronic fatigue syndrome, concussion, dementia, cervical and lumbar disc disease, dizziness, dystonia, epilepsy, Guillain-Barre syndrome, cluster headaches, tension headaches, migraines, motor neuron disease amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, neuralgia, neurofibromatosis, neuropathy, neuromuscular and related disorders, Parkinson's disease, progressive supranuclear palsy, severe depression, psychiatric conditions such as obsessive-compulsive disorder, sciatica, scoliosis, spasms, shingles, spinal cord injury, spinal deformity, spinal disorders, spinal tumors, stroke, traumatic brain injury, and vertigo.

[0367] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be used to treat psychiatric disorders.

[0368] Examples of suitable mental disorders include alcohol or substance use disorders; anxiety disorders, including generalized anxiety disorder, panic disorder, phobias, and social anxiety disorder; adult attention deficit / hyperactivity disorder; bipolar disorders, including major depressive episodes, hypomanic episodes, manic episodes, and mixed specifier (formerly mixed episodes); depression, including postpartum depression and seasonal affective disorder; eating disorders; obsessive-compulsive disorder; opioid use disorder symptoms; post-traumatic stress disorder; schizophrenia; dissociative disorders; feeding and eating disorders; sexual and paraphilic disorders; sleep and wake disorders; Asperger's disorder, autistic disorder, and Rett's disorder. childhood psychiatric disorders, including autism spectrum disorders such as ADHD, attention-deficit / hyperactivity disorder, and autism; personality disorders, including antisocial personality disorder, avoidant personality disorder, emotionally unstable personality disorder, dependent personality disorder, histrionic personality disorder, multiple personality disorder, dissociative identity disorder, narcissistic personality disorder, obsessive-compulsive personality disorder, paranoid personality disorder, schizoid personality disorder, and schizotypal personality disorder; and other psychiatric disorders, including acute stress disorder, Alzheimer's disease, Parkinson's disease, and psychotic disorders.

[0369] The psychiatric disorder may be selected from alcohol abuse disorders, substance abuse disorders, anxiety disorders, adult attention-deficit / hyperactivity disorder, bipolar disorder, obsessive-compulsive disorder, opioid use disorder, post-traumatic stress disorder, schizophrenia, dissociative disorders, eating and consumption disorders, sexual and paraphilic disorders, sleep and wake disorders, childhood psychiatric disorders, and personality disorders.

[0370] The psychiatric disorder may be selected from a mood disorder, a substance abuse disorder, and suicidal ideation.

[0371] The psychiatric disorder may be a mood disorder selected from post-traumatic stress syndrome, anxiety, bipolar disorder, and obsessive-compulsive disorder.

[0372] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be administered with other drugs known to be useful in the treatment of major depressive disorder.

[0373] Examples of drugs known to be useful in the treatment of major depression include selective serotonin reuptake inhibitors such as citalopram, escitalopram, and sertraline, and antidepressants such as bupropion, mirtazapine, imipramine, and nortriptyline, brexpiprazole, brintellix, budeprion, bupropan, bupropion, citalopram, duloxetine, desvenlafaxine, venlafaxine, escitalopram, luomilnacipran, fluoxetine, milnacipran, mirtazapine, nefazodone, olanzapine, tranylcypromine, paroxetine, paroxetine mesylate, and trazodone.

[0374] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be used to treat pain.

[0375] Examples of pain include acute pain, addiction, advanced prostate cancer, AIDS-related pain, ankylosing spondylitis, arachnoiditis, arthritis, arthrofibrosis, ataxic cerebral palsy, autoimmune atrophic gastritis, autoimmune diseases, avascular necrosis, low back pain, Behçet's disease (syndrome), breakthrough pain, burning mouth syndrome, bursitis, autosomal dominant cerebral arteriopathy, cancer pain, carpal tunnel, cauda equina syndrome, central pain syndrome, cerebral palsy, cerebrospinal fluid leak, cervical stenosis, Charcot-Marie-Tooth disease, chronic fatigue syndrome, chronic functional abdominal pain, chronic pain, chronic pancreatitis, coccyx, collapsed lung (pneumothorax), complementary and alternative medicine, complex regional pain syndrome, corneal neuropathic pain, Crohn's disease, degenerative disc disease, physical addiction, depression, Dercum's disease, dermatomyositis, diabetic peripheral neuropathy, dystonia, Ehlers-Danlos syndrome, endometriosis, and eosinophilia. Growing pain-myalgia syndrome, erythromycin, lumbar postoperative pain syndrome, fibromyalgia, gout, growing pains, headache, herniated disc, hydrocephalus, intercostal neuralgia, interstitial cystitis, irritable bowel syndrome, juvenile dermatomyositis, knee injury, lower limb pain, lumbar pain-hematuria syndrome, lupus, Lyme disease, sponge kidney, dysesthesias femoris, mesothelioma, migraine, mitochondrial disorders, multiple sclerosis, musculoskeletal pain, myofascial pain, myositis, neck pain, neuropathic pain Pain, NSAIDs, Occipital Neuralgia, Osteoarthritis, Paget's Disease, Parsonage-Turner Syndrome, Patient Rights, Pelvic Pain, Peripheral Neuropathy, Phantom Limb Pain, Nerve Compression, Polycystic Kidney Disease, Polymyalgia Rheumatica, Polymyositis, Porphyria, Post-Hemiparesis Pain Syndrome, Post-Mastectomy Pain Syndrome, Post-Stroke Pain, Post-Thraotomy Pain Syndrome, Post-Herpetic Neuralgia (Shingles), Post-Polio Health International, post-polio syndrome, post-traumatic stress disorder, primary lateral sclerosis, psoriatic arthritis, pudendal neuralgia, radiculopathy, Raynaud's disease, restless leg syndrome, rheumatoid arthritis, sacroiliac joint dysfunction, sarcoidosis, Scheuermann's kyphosis, sciatica, scoliosis, shingles (herpes zoster), sickle cell anemia, Sjogren's syndrome, sleep apnea, spasmodic torticollis, sphincter of Oddi dysfunction, spinocerebellar ataxia, spinal cord injury, spinal stenosis, syringomyelia, Tarlov cyst, tethered spinal cord syndrome, thoracic outlet syndrome, TMJ, intolerance, transverse myelitis, trigeminal neuralgia, trigger points, ulcerative colitis, vascular pain, vulvodynia, and whiplash injury.

[0376] Ketamine is an NMDA (N-methyl-D-aspartate) receptor antagonist. Thus, compounds provided by the present disclosure that release ketamine into the systemic circulation after oral administration may be useful in treating diseases for which ketamine and other NMDA receptor antagonists are useful in treating.

[0377] NMDA receptor antagonists are useful for treating, for example, acute pain, acute traumatic pain, alcohol use disorder, Alzheimer's disease, anxiety disorder, anxiety-related depression, autism spectrum disorder, bipolar depression, bipolar I disorder, bipolar II disorder, chronic pain, cancer pain, cognitive symptoms, cortical spreading depolarization, cortical spreading depression, violent / aggressive behavior, depression, fracture pain, head and neck cancer, headache, Huntington's disease, intractable pain, major depressive disorder, migraine, mood disorder, neuropathic pain, obsessive-compulsive disorder, and obstructive sleep apnea. They are known to be or thought to be useful in the treatment of sleep apnea syndrome, pancreatic cancer pain, Parkinson's disease, perinatal depression, postoperative cognitive dysfunction, postoperative pain, postpartum depression, post-traumatic stress disorder, pressure ulcers, psychotic-like symptoms, intractable cancer pain, Rett syndrome, schizophrenia, sleep apnea, social anxiety disorder, stress disorder, subarachnoid hemorrhage, substance use disorder, suicide, suicidal ideation, systemic lupus erythematosus, traumatic brain injury, treatment-resistant depression, and unipolar depression.

[0378] The pharmaceutical compositions and oral dosage forms provided by the present disclosure may be used to treat anxiety disorders, seasonal affective disorder, mania, bipolar disorder, obsessive-compulsive disorder, insomnia and fatigue resulting from jet lag, schizophrenia, convulsions, panic attacks, depression, alcoholism, drug addiction, alcoholism, substance abuse, drug addiction withdrawal, insomnia, psychotic disorders, epilepsy, sleep disorders, sleep apnea, compulsive eating disorder, fibromyalgia, stress, obesity, Parkinson's disease, cognitive impairment, memory impairment, premenstrual syndrome, migraine, memory loss, Alzheimer's subclinical disease, or disorders associated with normal or pathological aging.

[0379] The pharmaceutical compositions or oral dosage forms provided by the present disclosure can be used to treat diseases whose etiology is related to NMDA receptors.

[0380] The pharmaceutical compositions or oral dosage forms provided by the present disclosure can be administered to a patient in combination with drugs known to be useful in treating the side effects of ketamine, including drowsiness, dizziness, incoordination, blurred vision, dissociative symptoms, impaired attention and concentration, anxiety, and confusion.

[0381] Drugs known to be useful in treating the side effects of ketamine include, for example, clonidine.

[0382] Methods provided by the present disclosure include providing a therapeutically effective amount of ketamine in the systemic circulation of a patient, including administering pharmaceutical compositions and oral dosage forms provided by the present disclosure.

[0383] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be administered orally.

[0384] The pharmaceutical compositions and oral dosage forms provided by the present disclosure, when administered orally, provide enhanced oral bioavailability of ketamine compared to the oral bioavailability of orally administered ketamine.

[0385] In humans, orally administered (50 mg tablets) (S)-ketamine and (R)-ketamine have oral bioavailability of approximately 18%, C max is approximately 41 ng / mL, and T max is about 31 minutes, AUC o-inf is ng×h / mL. Yanagihara et al., Biopharmaceutics & Drug Disposition, 24, pp. 37-43 (2003).

[0386] For example, compounds of Formula (1) may exhibit an oral ketamine bioavailability (%F) of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least 60%. Compounds of Formula (1) may provide, for example, an oral ketamine bioavailability of 5% to 90%, 10% to 80%, 15% to 70%, or 20% to 60%.

[0387] Single and multiple doses of ketamine for treating disorders such as depression can range, for example, from 50 mg to 300 mg per day.

[0388] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be administered in conjunction with agents known to be or believed to be effective in treating the disorder being treated with ketamine.

[0389] For example, the pharmaceutical compositions and oral dosage forms provided by the present disclosure may be used in combination with other NMDA receptor antagonists, including competitive antagonists such as AP5 (APV, R-2-amino-5-phosphonopentanoate), AP7 (2-amino-7-phosphonoheptanoic acid), co-opene (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic acid), selfotel, and aspartame; minocycline, amantadine, atomoxetine, AZD6765, agmatine, chloroform, dextralorphan, dextromethorphan, dextrorphan, diphenidine, dizocilpine (MK-801), ethanol, eticlidine, gacyclidine, ketamine, magnesium, memantine, methoxetamine, nitromemantine, nitrous oxide, non-competitive channel blockers including PD-137889, phencyclidine, rolicyclidine, tenocyclidine, methoxyzine, tiletamine, neramexane, eliprodil, etoxadrol, dexoxadrol, WMS-2539, NEFA, limacemide, delusumaine, and 8A-PDHQ, non-competitive antagonists such as aptiganel, HU-211, huperzine A, ibogaine, limacemide, lyncophylline, and gabapentin; glycine antagonists such as apastinel, NRX-1074, 7-chlorokynurenic acid, 4-chlorokynurenine, 5,7-dichlorokynurenic acid, kynurenic acid, TK-40, 1-aminocyclopropanecarboxylic acid, l-phenylalanine, and xenon; or combinations of any of the foregoing.

[0390] The dose and appropriate administration interval of the compound of Formula (1) can be selected to maintain a sustained therapeutically effective concentration of the compound ketamine in the patient's blood, and in certain embodiments, can be selected without exceeding the minimum harmful concentration.

[0391] The therapeutically effective concentration of ketamine in a patient's blood or plasma can be below an amount that causes unacceptable adverse effects, including adverse effects on homeostasis. The therapeutically effective concentration of ketamine in a patient's blood or plasma can be an amount sufficient to restore and / or maintain homeostasis in the patient. For example, following administration of a therapeutically effective dose of a compound of Formula (1), a therapeutically effective amount of ketamine can be maintained for more than 1 hour, more than 2 hours, more than 3 hours, more than 4 hours, more than 5 hours, more than 6 hours, more than 7 hours, or more than 8 hours. For example, following administration of a therapeutically effective amount of a compound of Formula (1), a therapeutically effective amount of ketamine can be maintained for, for example, 1 hour to 10 hours, 2 hours to 8 hours, 2 hours to 6 hours, or 2 hours to 4 hours.

[0392] The patient's therapeutically effective plasma ketamine concentration can be, for example, greater than 5 ng / mL, greater than 10 ng / mL, greater than 20 ng / mL, greater than 50 ng / mL, greater than 100 ng / mL, greater than 150 ng / mL, or greater than 200 ng / mL, and the disease or condition is, for example, pain or depression.

[0393] For example, a therapeutically effective plasma ketamine concentration for treating pain or depression can range from 1 ng / mL to 250 ng / mL, 5 ng / mL to 200 ng / mL, 10 ng / mL to 175 ng / mL, or 50 ng / mL to 175 ng / mL.

[0394] For example, the therapeutically effective AUC for treating pain or depression 0-inf Plasma ketamine concentrations can range, for example, from 10 ng×h / mL to 500 ng×h / mL, from 50 ng×h / mL to 400 ng×h / mL, or from 100 ng×h / mL to 300 ng×h / mL.

[0395] For example, the dose of a compound of Formula (1) for treating a disorder such as pain or depression can range from 0.1 mg equivalents of ketamine / kg to 3 mg equivalents / kg, 0.5 mg equivalents / kg to 2.5 mg / kg, or 1 mg equivalents / kg to 2 mg / kg. For example, the dose of a compound of Formula (1) for treating a disorder such as pain or depression can be greater than 0.1 mg equivalents of ketamine / kg, greater than 0.5 mg equivalents / kg, greater than 1 mg equivalents / kg, or greater than 2 mg equivalents / kg.

[0396] For example, the dose of a compound of formula (1) for treating a disorder such as pain or depression can range from 10 mg equivalents of ketamine to 250 mg equivalents, 20 mg equivalents to 200 mg equivalents, or 25 mg equivalents to 100 mg equivalents.

[0397] For example, the dose of a compound of formula (1) for treating a disorder such as pain or depression can be greater than 10 mg equivalents of ketamine, greater than 25 mg equivalents, greater than 50 mg equivalents, greater than 75 mg equivalents, greater than 100 mg equivalents, greater than 150 mg equivalents, greater than 200 mg equivalents, or greater than 250 mg equivalents.

[0398] The oral dosage forms provided by the present disclosure can be administered at appropriate intervals for a suitable duration to treat the disease.

[0399] For example, once-daily, twice-daily, three-times-daily, or four-times-daily oral dosage forms may be determined.

[0400] Oral dosage forms can be administered for, for example, 1 to 7 days, 1 to 8 weeks, or 1 to 3 months.

[0401] The dosing interval and the dose administered may vary during treatment.

[0402] The pharmaceutical compositions and oral dosage forms provided by the present disclosure can be included in kits that can be used to administer the pharmaceutical composition or oral dosage form to a patient for therapeutic purposes. The kits can include a pharmaceutical composition or oral dosage form comprising a compound of Formula (1) suitable for administration to a patient, and instructions for administering the pharmaceutical composition or oral dosage form to the patient. A kit for use in treating a disorder, such as a psychiatric disorder, a neurological disorder, or pain, in a patient can include a pharmaceutical composition or oral dosage form provided by the present disclosure, a pharmaceutically acceptable vehicle for administering the pharmaceutical composition or oral dosage form, and instructions for administering the pharmaceutical composition or oral dosage form to the patient. Instructions provided with the kit can be printed and / or provided, for example, as an electronically readable medium, video cassette, audio tape, flash memory device, or published on an internet website or distributed to patients and / or healthcare providers as electronic communications.

[0403] Aspects of the present invention The present invention is further defined by the following aspects.

[0404] Aspect 1. A pharmaceutical composition comprising: A compound of formula (1), [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen and C 1-6 alkyl, R 2 is selected from a moiety of formula (2), a moiety of formula (3), a moiety of formula (4), and a moiety of formula (5), [ka] During the ceremony, R 3 is hydrogen, C 1-6 Alkyl, C 7-12 Alkyl arenes and substituted C 7-12 selected from alkylarenes, R 4 is hydrogen and C 1-6 alkyl, R5 is hydrogen, C 1-6 alkyl, —C(═O)—R10, and —C(═O)—O—R10, wherein R 10 is C 1-6 Alkyl, C 3-6 cycloalkyl, and —CF3; R 6 is C 1-6 Alkyl and C 1-6 alkoxy; n is an integer from 0 to 3, R7 is hydrogen, C 1-6 Alkyl, -C(=O)-R11, and -C(=O)-OR 10 is selected from: R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl; R 11 -NH2, -CF3, C 1-6 Alkyl, and C 3-6 cycloalkyl; R 9 is hydrogen and C 1-3 granules comprising a compound of formula (1), or a pharmaceutically acceptable salt thereof, selected from alkyl; a controlled release polymer; and an anionic sulfate / sulfonate surfactant.

[0405] Aspect 2. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (62): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0406] Aspect 3. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (63): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0407] Aspect 4. The compound of formula (1) is (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (22) and (R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (66): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0408] Aspect 5. The compound of formula (1) is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39) and ((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (65): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0409] Aspect 6. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (58) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (71): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0410] Aspect 7. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (59) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (72): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0411] Aspect 8. The composition of aspect 1, wherein the compound of formula (1) is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39), or a pharmaceutically acceptable salt thereof.

[0412] Aspect 9. The composition of any one of Aspects 1-8, wherein the compound of Formula (1) comprises a hydrochloride salt.

[0413] Aspect 10. The composition of any one of Aspects 1-8, wherein the compound of Formula (1) comprises the free base.

[0414] Aspect 11. The composition of any one of Aspects 1 to 10, wherein the compound of Formula (1) or a pharmaceutically acceptable salt thereof has a higher solubility in 0.1 N hydrochloride salt than in 50 mM acetate buffer at pH 4.5.

[0415] Aspect 12. The composition of any one of aspects 1-11, wherein the granule comprises greater than 95% by weight of the compound of Formula (1) or a pharmaceutically acceptable salt thereof, wherein the weight percentage is based on the total weight of the granule.

[0416] Embodiment 13. The composition of any one of embodiments 1 to 12, wherein the granules comprise a granule binder.

[0417] Aspect 14. The composition of aspect 13, wherein the granule binder comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, or a combination of any of the foregoing.

[0418] Aspect 15. The composition of aspect 13 or 14, wherein the granules comprise 0.5 wt% to 5.0 wt% of a granule binder, the wt% being based on the total weight of the granule.

[0419] Aspect 16. Granules, 97% to 99% by weight of a compound of formula (1) or a pharmaceutically acceptable salt thereof; 1% to 3% by weight of a granule binder; 16. The composition of any one of aspects 1-15, wherein the wt% is based on the total weight of the granules.

[0420] Embodiment 17. The composition of any one of embodiments 1 to 16, wherein the granules have an average diameter of 100 μm to 500 μm.

[0421] Embodiment 18. The composition of any one of embodiments 1 to 17, wherein the composition comprises 35% to 55% by weight of granules, the weight percentages being based on the total weight of the composition.

[0422] Aspect 19. The composition of any one of aspects 1-18, wherein the controlled-release polymer comprises a carbomer copolymer, shellac, a carbomer homopolymer, hypromellose (hydroxypropyl methylcellulose) polymer, a carbomer interpolymer, sodium carboxymethylcellulose, carrageenan, cerabrate, ethylcellulose, glyceryl monooleate, pregelatinized modified starch, glyceryl monostearate, guar gum, hydroxypropyl betadex, hydroxypropyl cellulose, polyethylene oxide, polyvinyl acetate dispersion, sodium alginate, pregelatinized starch, xanthan gum, alginic acid, ethyl acrylate / methyl methacrylate copolymer, acrylic acid / allylsucrose polymer, acrylic acid / allylpentaerythritol polymer, acrylic acid / alkyl acrylate / allylpentaerythritol copolymer, or a combination of any of the foregoing.

[0423] Embodiment 20. The composition of any one of embodiments 1-19, wherein the controlled release polymer comprises hydroxypropyl methylcellulose.

[0424] Aspect 21. The composition of aspect 20, wherein the hydroxypropyl methylcellulose is characterized by a weight average molecular weight of 900,000 daltons to 1,100,000 daltons, a methoxyl content of 20% to 24%, a pH of 5 to 8 at 25°C, a hydroxypropyl content of 7% to 12%, and a viscosity of a 2% aqueous solution at 20°C of 75,000 mPa-s (cP) to 140,000 mPa-s (cP).

[0425] Aspect 22. The composition of aspect 20 or 21, wherein the hydroxypropyl methylcellulose is characterized by a weight average molecular weight of 300,000 daltons to 500,000 daltons, a methoxyl content of 19% to 24%, a pH of 5 to 8 at 25°C, a hydroxypropyl content of 7% to 12%, and a viscosity of a 2% aqueous solution at 20°C of 2,700 cP mPa-s to 5,040 cP mPa-s.

[0426] Aspect 23. Hydroxypropyl methylcellulose is 50% to 80% by weight of hydroxypropyl methylcellulose characterized by a weight average molecular weight of 900,000 to 1,100,000 daltons, and 20% to 50% by weight of hydroxypropyl methylcellulose characterized by a weight average molecular weight of 300,000 to 500,000 daltons; Aspect 23. The composition of any one of aspects 20-22, wherein the weight percentages are based on the total weight of the hydroxypropyl methylcellulose.

[0427] Embodiment 24. The composition of any one of embodiments 1 to 23, wherein the composition comprises 10% to 40% by weight of the controlled release polymer, wherein the weight percentage is based on the total weight of the composition.

[0428] Embodiment 25. The composition of any one of embodiments 1 to 24, wherein the anionic sulfate / sulfonate surfactant is characterized by a critical micelle concentration of 2 g / L to 3 g / L (6.9 mmol / L to 10.4 mmol / L) at 20° C.

[0429] Embodiment 26. The composition of any one of embodiments 1 to 25, wherein the anionic sulfate / sulfonate surfactant comprises sodium lauryl sulfate.

[0430] Embodiment 27. The composition of embodiment 26, wherein the sodium lauryl sulfate is characterized by a critical micelle concentration of 2.2 g / L to 2.5 g / L at 20°C.

[0431] Embodiment 28. The composition of any one of embodiments 1 to 27, wherein the composition comprises 5% to 15% by weight of anionic sulfate / sulfonate surfactant, the weight percentages being based on the total weight of the composition.

[0432] Embodiment 29. The composition comprises: 30% to 60% by weight of granules; 10% to 40% by weight of a controlled release polymer; 5% to 15% by weight of an anionic sulfate / sulfonate surfactant; Aspect 29. The composition of any one of aspects 1-28, wherein the wt% is based on the total weight of the composition.

[0433] Embodiment 30. The composition of any one of embodiments 1 to 29, wherein the composition comprises a filler.

[0434] Embodiment 31. The composition of embodiment 30, wherein the filler comprises microcrystalline cellulose.

[0435] Embodiment 32. The composition of embodiment 30 or 31, wherein the composition comprises 5% to 35% by weight of the filler, the weight percentage being based on the total weight of the composition.

[0436] Embodiment 33. The composition of any one of embodiments 1 to 32, wherein the composition comprises a lubricant.

[0437] Aspect 34. The composition of Aspect 33, wherein the lubricant comprises magnesium stearate.

[0438] Aspect 35. The composition of aspect 32 or 33, wherein the composition comprises 0.1% to 1.5% by weight of a lubricant, the weight percentage being based on the total weight of the composition.

[0439] Embodiment 36. An oral dosage form comprising the composition of any one of embodiments 1 to 35.

[0440] Embodiment 37. The composition of embodiment 36, wherein the oral dosage form comprises a solid oral dosage form.

[0441] The composition of embodiment 36, wherein the oral dosage from embodiment 38 comprises a tablet.

[0442] Aspect 39. The oral dosage form of any one of Aspects 36 to 38, wherein the oral dosage form comprises between 25 mg and 400 mg of the compound of Formula (1) or a pharmaceutically acceptable salt thereof.

[0443] Aspect 40. The oral dosage form exhibits a zero-order release profile of the compound of formula (1) or a pharmaceutically acceptable salt thereof over a 6 hour duration in a two-stage dissolution medium when determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.; the first step comprising soaking the solid dose from in 0.1 N hydrochloric acid for 1 hour; 40. The oral dosage form of any one of aspects 36-39, wherein the second step comprises immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time.

[0444] Aspect 41. An oral dosage form characterized by a dissolution profile of a compound of formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 20% to 40% of the compound of formula (1) is released in 2 hours; 30% to 50% of the compound of formula (1) is released in 4 hours, 70% to 80% of the compound of formula (1) is released in 8 hours, 80% to 100% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours, The first step involves soaking an oral dose from in 0.1N hydrochloric acid for 1 hour; The second step involves immersing the oral dose from in 50 mM acetate buffer at pH 4.5 for a sustained period of time; 41. The oral dosage form of any one of aspects 36 to 40, wherein the percentage (%) is based on the total amount of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form.

[0445] Aspect 42. A solid dosage form characterized by a dissolution profile of a compound of formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 30% to 40% is the compound of formula (1) released in 2 hours; 50% to 70% of the compound of formula (1) is released in 4 hours; 70% to 90% of the compound of formula (1) is released in 8 hours; More than 90% of the compound of formula (1) is released in 12 hours; The first step involves immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; the second step involves immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time; 41. The oral dosage form of any one of aspects 36 to 40, wherein the percentage (%) is based on the total amount of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form.

[0446] Aspect 43. A solid dosage form characterized by a dissolution profile of a compound of formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 15% to 25% of the compound of formula (1) is released in 2 hours; 20% to 35% is the compound of formula (1) released in 4 hours; 50% to 60% of the compound of formula (1) is released in 8 hours; 70% to 85% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours; the first step comprising immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; 41. The oral dosage form of any one of aspects 36-40, wherein a second step comprises immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period, wherein the percentage (%) is based on the total amount of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form.

[0447] Embodiment 44. The oral dosage form of any one of embodiments 36-40, wherein the dissolution profile is bioequivalent to any one of the dissolution profiles shown in FIG. 1.

[0448] Aspect 45. A kit comprising the pharmaceutical composition according to any one of aspects 1 to 35, or the oral dosage form according to any one of aspects 36 to 44.

[0449] Aspect 46. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of any one of Aspects 1 to 35, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0450] Embodiment 47. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of any one of embodiments 1 to 35, wherein the disease is treated by inhibiting the NMDA receptor.

[0451] Aspect 48. A method for treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of the oral dosage form of any one of aspects 36 to 44, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0452] Embodiment 49. A method for treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of an oral dosage form according to any one of embodiments 36 to 44, wherein the disease is treated by inhibiting the NMDA receptor.

[0453] Aspect 50. Use of a pharmaceutical composition according to aspect 1 in the manufacture of a medicament for treating a disease in a patient, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0454] Embodiment 51. Use of a pharmaceutical composition according to any one of embodiments 1 to 35 in the manufacture of a medicament for treating a disease in a patient, wherein the disease is treated by inhibiting NMDA receptors.

[0455] Aspect 1A. A pharmaceutical composition comprising: (a) a compound of formula (1), [ka] or a pharmaceutically acceptable salt thereof, wherein: R 1 is hydrogen and C 1-6 alkyl, R 2 is selected from a moiety of formula (2), a moiety of formula (3), a moiety of formula (4), and a moiety of formula (5), [ka] During the ceremony, R 3 is hydrogen, C 1-6 Alkyl, C 7-12 Alkyl arenes and substituted C 7-12 selected from alkylarenes, R 4 is hydrogen and C 1-6 alkyl, R5 is hydrogen, C 1-6alkyl, —C(═O)—R10, and —C(═O)—O—R10, wherein R 10 is C 1-6 Alkyl, C 3-6 cycloalkyl, and —CF3; R 6 is C 1-6 Alkyl and C 1-6 alkoxy; n is an integer from 0 to 3, R7 is hydrogen, C 1-6 Alkyl, -C(=O)-R11, and -C(=O)-OR 10 is selected from: R 10 is C 1-6 Alkyl and C 3-6 cycloalkyl; R 11 -NH2, -CF3, C 1-6 Alkyl, and C 3-6 cycloalkyl; R 9 is hydrogen and C 1-3 a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of alkyl, (b) a controlled release polymer; and (c) an anionic sulfate / sulfonate surfactant.

[0456] Aspect 2A. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (62): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0457] Aspect 3A. The compound of Formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (63): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0458] Aspect 4A. The compound of Formula (1) is (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (22) and (R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (66): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0459] Aspect 5A. The compound of formula (1) is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-L-valinate (39) and ((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl dimethyl-L-valinate (65): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0460] Aspect 6A. The compound of Formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (58) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (71): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0461] Aspect 7A. The compound of Formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (59) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-alloisoleucinate (72): [ka] [ka] or a pharmaceutically acceptable salt of any of the foregoing.

[0462] Aspect 8A. The pharmaceutical composition of Aspect 1A, wherein the compound of Formula (1) is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39), or a pharmaceutically acceptable salt thereof.

[0463] Aspect 9A. The pharmaceutical composition of any one of Aspects 1A-8A, wherein the compound of Formula (1) comprises the hydrochloride salt.

[0464] Aspect 10A. The pharmaceutical composition of any one of Aspects 1A-8A, wherein the compound of Formula (1) comprises the free base.

[0465] Aspect 11A. The pharmaceutical composition of any one of Aspects 1A-10A, wherein the compound of Formula (1) or a pharmaceutically acceptable salt thereof has a higher solubility in 0.1 N hydrochloride salt than in 50 mM acetate buffer at pH 4.5.

[0466] Aspect 12A. The pharmaceutical composition of any one of Aspects 1A-11A, wherein the pharmaceutical composition comprises granules, the granules comprising greater than 95% by weight of a compound of Formula (1) or a pharmaceutically acceptable salt thereof, wherein the weight percentage is based on the total weight of the granules.

[0467] Aspect 13A. The pharmaceutical composition of Aspect 12A, wherein the granules comprise a granule binder.

[0468] Aspect 14A. The pharmaceutical composition of Aspect 13A, wherein the granule binder comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, or a combination of any of the foregoing.

[0469] Aspect 15A. The pharmaceutical composition of Aspect 14A, wherein the granule binder comprises hydroxypropyl methylcellulose.

[0470] Aspect 16A. The pharmaceutical composition of Aspect 15A, wherein the hydroxypropyl methylcellulose is characterized as a 2910 substitution type and characterized by a viscosity of 3 mPa×sec in a 2 wt % aqueous solution at 20° C.

[0471] Aspect 17A. The pharmaceutical composition of any one of Aspects 13A to 16A, wherein the granules comprise between 0.5% and 5.0% by weight of granule binder, wherein the weight percentages are based on the total weight of the granules.

[0472] Aspect 18A. Granules comprising: 97% to 99% by weight of a compound of formula (1) or a pharmaceutically acceptable salt thereof; 1% to 3% by weight of a granule binder; A pharmaceutical composition according to any one of Aspects 13A to 17A, wherein the weight percentages are based on the total weight of the granules.

[0473] Aspect 19A. The pharmaceutical composition of any one of Aspects 13A to 18A, wherein the granules have an average diameter of between 100 μm and 500 μm as determined by sieve analysis or laser diffraction.

[0474] Aspect 20A. The pharmaceutical composition of any one of Aspects 13A to 19A, wherein the pharmaceutical composition comprises 35% to 55% by weight of granules, the weight percentages being based on the total weight of the pharmaceutical composition.

[0475] Aspect 21A. The pharmaceutical composition of any one of Aspects 1A-20A, wherein the controlled release polymer comprises a carbomer copolymer, shellac, a carbomer homopolymer, hypromellose (hydroxypropyl methylcellulose) polymer, a carbomer interpolymer, sodium carboxymethylcellulose, carrageenan, cerabrate, ethylcellulose, glyceryl monooleate, pregelatinized modified starch, glyceryl monostearate, guar gum, hydroxypropyl betadex, hydroxypropyl cellulose, polyethylene oxide, polyvinyl acetate dispersion, sodium alginate, pregelatinized starch, xanthan gum, alginic acid, ethyl acrylate / methyl methacrylate copolymer, acrylic acid / allylsucrose polymer, acrylic acid / allylpentaerythritol polymer, acrylic acid / alkyl acrylate / allylpentaerythritol copolymer, or a combination of any of the foregoing.

[0476] Aspect 22A. The pharmaceutical composition of any one of Aspects 1A-20A, wherein the controlled release polymer comprises hydroxypropyl methylcellulose.

[0477] Aspect 23A. The pharmaceutical composition of Aspect 22A, wherein the hydroxypropyl methylcellulose is characterized by a 22% to 24% methoxyl content, a pH of 5 to 8 in 2% water at 25°C, a 7.5% to 9.5% hydroxypropoxyl content, and a viscosity of 80 mPa-s (cP) to 120 mPa-s (cP) as a 2% aqueous solution at 20°C.

[0478] Aspect 24A. The pharmaceutical composition of Aspect 22A or 23A, wherein the hydroxypropyl methylcellulose is characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 in 2% water at 25°C, a hydroxypropoxyl content of 7.5% to 9.5%, and a viscosity (Brookfield) of 2,600 cP mPa-s to 5,000 cP mPa-s as a 2% aqueous solution at 20°C.

[0479] Aspect 25A. Hydroxypropyl methylcellulose is 50% to 100% by weight of hydroxypropyl methylcellulose, characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 in 2% water at 25°C, a hydroxypropoxyl content of 7.5% to 9.5%, and a viscosity of 80 mPa-s (cP) to 120 mPa-s (cP) as a 2% aqueous solution at 20°C; and 0% to 50% by weight of hydroxypropyl methylcellulose characterized by a 22% to 24% methoxyl content, a pH of 5 to 8 in 2% water at 25°C, a 7.5% to 9.5% hydroxypropoxyl content, and a viscosity (Brookfield) of 2,600 cP mPa-s to 5,000 cP mPa-s as a 2% aqueous solution at 20°C; The pharmaceutical composition of any one of Aspects 22A to 24A, wherein the weight percentages are based on the total weight of the hydroxypropyl methylcellulose.

[0480] Aspect 26A. The pharmaceutical composition of any one of Aspects 1A-25A, wherein the pharmaceutical composition comprises 10% to 60% by weight of the controlled release polymer, wherein the weight percentage is based on the total weight of the pharmaceutical composition.

[0481] Aspect 27A. The pharmaceutical composition of any one of Aspects 1A-26A, wherein the anionic sulfate / sulfonate surfactant is characterized by a critical micelle concentration of 2 g / L to 3 g / L (6.9 mmol / L to 10.4 mmol / L) at 20° C.

[0482] Aspect 28A. The pharmaceutical composition of any one of Aspects 1A-27A, wherein the anionic sulfate / sulfonate surfactant comprises sodium lauryl sulfate.

[0483] Aspect 29A. The pharmaceutical composition of Aspect 28A, wherein the sodium lauryl sulfate is characterized by a critical micelle concentration of 2.2 g / L to 2.5 g / L at 20° C.

[0484] Aspect 30A. The pharmaceutical composition of any one of Aspects 1A-29A, wherein the pharmaceutical composition comprises 5% to 15% by weight of anionic sulfate / sulfonate surfactant, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

[0485] Aspect 31A. The pharmaceutical composition of any one of Aspects 1A-30A, wherein the pharmaceutical composition comprises a filler material.

[0486] Aspect 32A. The pharmaceutical composition of Aspect 31A, wherein the filler material comprises microcrystalline cellulose.

[0487] Aspect 33A. The pharmaceutical composition of Aspect 31A or 32A, wherein the pharmaceutical composition comprises 5% to 35% by weight of a filler, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

[0488] Aspect 34A. The pharmaceutical composition of any one of Aspects 1A-33A, wherein the pharmaceutical composition comprises a lubricant.

[0489] Aspect 35A. The pharmaceutical composition of Aspect 34A, wherein the lubricant comprises magnesium stearate.

[0490] Aspect 36A. The pharmaceutical composition of Aspect 34A or 35A, wherein the pharmaceutical composition comprises 0.1% to 1.5% by weight of a lubricant, wherein the weight percentage is based on the total weight of the pharmaceutical composition.

[0491] Aspect 37A. The pharmaceutical composition comprises: 30% to 60% by weight of granules; 10% to 60% by weight of a controlled release polymer; 5% to 15% by weight of an anionic sulfate / sulfonate surfactant; The pharmaceutical composition of any one of Aspects 1A to 36A, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

[0492] Aspect 38A. The pharmaceutical composition comprises: 35% to 55% by weight of granules; 20% to 40% by weight of a controlled release polymer; 10% to 20% by weight of a filler; 5% to 15% by weight of an anionic sulfate / sulfonate surfactant; 0.1 wt % to 1.0 wt % of a lubricant; The pharmaceutical composition of any one of Aspects 1A to 36A, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

[0493] Embodiment 39A. The controlled release polymer comprises hydroxypropyl methylcellulose; the filler comprises microcrystalline cellulose; the anionic sulfate / sulfonate surfactant comprises sodium lauryl sulfate; The pharmaceutical composition of Aspect 38A, wherein the lubricant comprises magnesium stearate.

[0494] Aspect 40A. The pharmaceutical composition of any one of Aspects 1A-39A, wherein the pharmaceutical composition comprises a granulation.

[0495] Aspect 41A. The pharmaceutical composition of any one of Aspects 1A-39A, wherein the pharmaceutical composition comprises a tablet oral dosage form.

[0496] Aspect 42A. An oral dosage form prepared from the pharmaceutical composition of any one of Aspects 1A-41A.

[0497] Aspect 43A. An oral dosage form comprising the pharmaceutical composition of any one of Aspects 1A-41A.

[0498] Embodiment 44A. The oral dosage form of embodiment 43A, wherein the oral dosage form comprises a solid oral dosage form.

[0499] Embodiment 45A. The oral dosage form of embodiment 43A, wherein the oral dosage form comprises a tablet.

[0500] Aspect 46A. The oral dosage form of any one of Aspects 42A to 45A, wherein the oral dosage form comprises between 25 mg and 400 mg of a compound of Formula (1) or a pharmaceutically acceptable salt thereof.

[0501] Aspect 47A. The oral dosage form comprises: 35% to 55% by weight of a compound of formula (1); 0.5% to 1.5% by weight of hydroxypropyl methylcellulose E3; The oral dosage form of any one of aspects 42A to 46A, wherein the weight percentages are based on the total weight of the oral dosage form.

[0502] Aspect 48A. The oral dosage form comprises: 35% to 55% by weight of a compound of formula (1); 0.5% to 1.5% by weight of hydroxypropyl methylcellulose E3; 20% to 40% by weight of a controlled release polymer; 10% to 20% by weight of microcrystalline cellulose; 5% to 15% by weight of sodium lauryl sulfate; 0.1% to 1.0% by weight of magnesium stearate, The oral dosage form of any one of aspects 42A to 46A, wherein the weight percentages are based on the total weight of the tablet dosage form.

[0503] Aspect 49A. The oral dosage form of Aspect 48A, wherein the controlled release polymer is selected from hydroxypropyl methylcellulose K100 Premium LV DC2, hydroxypropyl methylcellulose K4M Premium DC2, or a combination thereof.

[0504] Aspect 50A. The oral dosage form of any one of Aspects 46A-49A, wherein the compound of Formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39).

[0505] Aspect 51A. The oral dosage form of any one of Aspects 46A-49A, wherein the compound of Formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39)HCl.

[0506] Aspect 52A. A tablet oral dosage form exhibits a zero order release profile of the compound of formula (1) or a pharmaceutically acceptable salt thereof over a 6 hour duration in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.; the first step involves immersing the tablet dosage form in 0.1 N hydrochloric acid for 1 hour; The oral dosage form of any one of aspects 45A to 51A, wherein the second step comprises immersing the tablet dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time.

[0507] Aspect 53A. A tablet oral dosage form characterized by a dissolution profile of the compound of Formula (1), or a pharmaceutically acceptable salt thereof, in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 20% to 40% of the compound of formula (1) is released in 2 hours; 30% to 50% of the compound of formula (1) is released in 4 hours; 70% to 80% of the compound of formula (1) is released in 8 hours; 80% to 100% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours; the first step comprising immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; a second step comprising immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time; The oral dosage form of embodiment 52A, wherein the percentage (%) is based on the total amount of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form before immersion.

[0508] Aspect 54A. A tablet oral dosage form characterized by a dissolution profile of the compound of Formula (1), or a pharmaceutically acceptable salt thereof, in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 30% to 40% of the compound of formula (1) is released in 2 hours; 50% to 70% of the compound of formula (1) is released in 4 hours; 70% to 90% of the compound of formula (1) is released in 8 hours; More than 90% of the compound of formula (1) is released in 12 hours; the first step comprising immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; a second step comprising immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time; The oral dosage form of embodiment 52A, wherein the percentage (%) is based on the total amount of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form before immersion.

[0509] Aspect 55A. A tablet oral dosage form characterized by a dissolution profile of the compound of Formula (1), or a pharmaceutically acceptable salt thereof, in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37° C.: 15% to 25% of the compound of formula (1) is released in 2 hours; 20% to 35% of the compound of formula (1) is released in 4 hours; 50% to 60% of the compound of formula (1) is released in 8 hours; 70% to 85% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours; the first step comprising immersing the oral dosage form in 0.1 N hydrochloric acid for 1 hour; a second step comprising immersing the oral dosage form in 50 mM acetate buffer at pH 4.5 for a sustained period of time; The oral dosage form of embodiment 52A, wherein the percentage (%) is based on the total amount of the compound of Formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form before immersion.

[0510] Embodiment 56A. The oral dosage form of embodiment 52A, wherein the two-stage dissolution profile is bioequivalent to any one of the dissolution profiles shown in FIG.

[0511] Aspect 57A. The oral dosage form of any one of Aspects 45A to 56A, wherein, following oral administration of a tablet dosage form comprising 100 mg of the compound of Formula (1) to a population of fasted healthy subjects, the AUC of the plasma esketamine concentration is between 60 h×ng / mL and 120 h×ng / mL and / or the AUC of the plasma noresketamine concentration is between 850 h×ng / mL and 1,000 h×ng / mL.

[0512] Aspect 58A. The oral dosage form of any one of Aspects 45A-57A, wherein, following oral administration of a tablet oral dosage form comprising 100 mg of the compound of Formula (1) to a population of fasted healthy subjects, the maximum plasma esketamine concentration is between 5 ng / mL and 10 ng / mL and / or the maximum plasma norketamine concentration is between 40 ng / mL and 80 ng / mL.

[0513] Aspect 59A. The oral dosage form of any one of Aspects 45A-58A, wherein following oral administration of a tablet oral dosage form comprising 100 mg to 400 mg of the compound of Formula (1) to a population of fasted healthy subjects, the maximum plasma esketamine concentration is less than 30 ng / mL and / or the maximum plasma noresketamine concentration is less than 250 ng / mL.

[0514] Aspect 60A. The oral dosage form of any one of Aspects 45A-59A, wherein following oral administration of a tablet oral dosage form comprising 100 mg to 400 mg of a compound of Formula (1) to a population of fasted healthy subjects, the ratio of esketamine Cmax / Cave(0 h-24 h) is 2 to 4, where Cmax is the maximum plasma esketamine concentration and Cave(0 h-24 h) is the mean plasma esketamine concentration from 0 hours to 24 hours after oral administration of the tablet dosage form.

[0515] Aspect 61A. The oral dosage form of any one of Aspects 45A-60A, wherein following oral administration of a tablet oral dosage form comprising 100 mg to 400 mg of a compound of Formula (1) to a population of fasted healthy subjects, the ratio of esketamine Cmax / Cave(0 h-24 h) is between 2.5 and 3.5, where Cmax is the maximum plasma esketamine concentration and Cave(0 h-24 h) is the mean plasma esketamine concentration from 0 hours to 24 hours after oral administration of the tablet dosage form.

[0516] Aspect 62A. The oral dosage form of any one of Aspects 45A-61A, wherein following oral administration of a tablet oral dosage form comprising 100 mg to 400 mg of a compound of Formula (1) to a population of fasted healthy subjects, the ratio of Cmax / Cave(0 h-24 h) of noresketamine is 1 to 3, where Cmax is the maximum plasma noresketamine concentration and Cave(0 h-24 h) is the mean plasma noresketamine concentration from 0 hours to 24 hours after oral administration of the tablet dosage form.

[0517] Aspect 63A. The oral dosage form of any one of Aspects 45A-62A, wherein following oral administration of a tablet oral dosage form comprising 100 mg to 400 mg of a compound of Formula (1) to a population of fasted healthy subjects, the ratio of Cmax / Cave(0 h-24 h) of noresketamine is between 1.5 and 2.5, where Cmax is the maximum plasma noresketamine concentration and Cave(0 h-24 h) is the plasma noresketamine concentration between 0 hours and 24 hours after oral administration of the tablet dosage form.

[0518] Aspect 64A. The oral dosage form of any one of Aspects 52A-63A, wherein the compound of Formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39).

[0519] Aspect 65A. The oral dosage form of any one of Aspects 52A-63A, wherein the compound of Formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39)HCl.

[0520] Aspect 66A. A kit comprising the pharmaceutical composition of any one of aspects 1A-41A or the oral dosage form of any one of aspects 42A-65A.

[0521] Aspect 67A. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition of any one of aspects 1A-41A or an oral dosage form of any one of aspects 42A-65A, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0522] Embodiment 68A. The method of embodiment 67A, wherein the disease is depression.

[0523] Aspect 69A. The method of aspect 68A, wherein the depression is selected from major depressive disorder, dysthymia, persistent depressive disorder, bipolar disorder, seasonal affective disorder, psychotic depression, perinatal depression, premenstrual dysphoric disorder, situational depression, atypical depression, treatment-resistant depression, endogenous depression, cyclothymic disorder, and profound mood dysregulation disorder.

[0524] Embodiment 70A. The method of embodiment 68A, wherein the depression is major depressive disorder.

[0525] Aspect 71A. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of any one of Aspects 1A-41A, wherein the disease is treated by inhibiting the NMDA receptor.

[0526] Aspect 72A. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of an oral dosage form of any one of Aspects 42A-65A, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0527] Embodiment 73A. The method of embodiment 72A, wherein the disease is depression.

[0528] Aspect 74A. The method of Aspect 73A, wherein the depression is selected from major depressive disorder, dysthymia, persistent depressive disorder, bipolar disorder, seasonal affective disorder, psychotic depression, perinatal depression, premenstrual dysphoric disorder, situational depression, atypical depression, treatment-resistant depression, endogenous depression, cyclothymic disorder, and profound mood dysregulation disorder.

[0529] Embodiment 75A. The method of embodiment 73A, wherein the depression is major depressive disorder.

[0530] Aspect 76A. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of an oral dosage form of any one of aspects 42A to 65A, wherein the disease is treated by inhibiting the NMDA receptor.

[0531] Aspect 77A. Use of a pharmaceutical composition according to any one of aspects 1 to 41 in the manufacture of a medicament for treating a disease in a patient, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

[0532] Embodiment 78. The use according to embodiment 77A, wherein the disease is depression.

[0533] Aspect 79A. The use of aspect 78, wherein the depression is selected from major depressive disorder, dysthymia, persistent depressive disorder, bipolar disorder, seasonal affective disorder, psychotic depression, perinatal depression, premenstrual dysphoric disorder, situational depression, atypical depression, treatment-resistant depression, endogenous depression, cyclothymic disorder, and profound mood dysregulation disorder.

[0534] Embodiment 80A. The use of embodiment 78A, wherein the depression is major depressive disorder.

[0535] Aspect 81A. Use of a pharmaceutical composition according to any one of Aspects 1A to 41A in the manufacture of a medicament for treating a disease in a patient, wherein the disease is treated by inhibiting NMDA receptors. [Example]

[0536] The following examples describe in detail the pharmaceutical compositions and oral dosage forms provided by the present disclosure. It will be apparent to those skilled in the art that many modifications, both to materials and methods, can be practiced without departing from the scope of the present disclosure.

[0537] In the examples, the ketamine derivative compound (39) was formulated as the hydrochloride salt.

[0538] The pharmacokinetic parameters disclosed in this application were calculated using Phoenix® WinNonlin® version 8.2 software, available from Certara Corporation, Menlo Park, CA, which is used for noncompartmental analysis, pharmacokinetic / pharmacodynamic, and toxicokinetic modeling. Pharmacokinetic parameters were calculated for each subject based on actual rather than protocol nominal time. Area under the curve (AUC) parameters were calculated using the linear trapezoidal rule from time 0 to the target time point. For example, AUC was calculated from time 0 to 6 hours (AUC 0-6h ) and time 0 to infinity (AUC 0-inf AUC was calculated for the duration of 0-6 For , if the actual time elapsed during the 6-hour collection period was not exactly 6 hours, the concentration at 6 hours post-dose was estimated by extrapolation using the half-life slope estimate. 0-inf was calculated using the following formula: AUC 0-inf =AUC 0-last +C plast / gradient (where AUC 0-last is the time from time 0 to the last measurable concentration (C plast ) where AUC is the AUC up to the time point of (AUC = 0.05, slope is the half-life slope). The half-life slope was calculated using linear regression of the terminal portion of the natural log concentration versus time profile.

[0539] Example 1 Granulation To prepare the granulation, the ketamine derivative of formula (1), the binder, and the amount of water shown in Table 1 were blended using a GMX Granumeist® high shear granulator. [Table 1]

[0540] The dry ingredients were added to the GMX bowl and mixed for 1 minute at an impeller speed of 870 RPM. Mist water was added to the GMX bowl at 1.0 g / min while mixing at an impeller speed of 850 RPM and a chopper speed of 3600 rpm. The ingredients were wet massed for 5 minutes during the water addition at 560 rpm and oven dried for approximately 14 hours at 40°C and 0.2% LOD.

[0541] The milled granules had an average particle diameter of about 250 μm when sieved through a 30 mesh screen. Specific properties of the milled granulation are shown in Table 2. [Table 2]

[0542] Example 2 Pharmaceutical compositions containing sodium lauryl sulfate Pharmaceutical compositions with and without sodium lauryl sulfate were prepared as described in Example 3, and tablets were prepared as described in Example 4. The ingredients of the tablets are shown in Table 3. [Table 3]

[0543] A two-phase dissolution profile showing the amount of compound 39 released over time for sodium lauryl sulfate-containing tablets is shown in Figure 2. The transition line indicates the time when the dissolution medium was changed from 0.1 N HCl to 50 mM pH 4.5 acetate buffer.

[0544] A two-phase dissolution profile was obtained as described in Example 5.

[0545] As shown in Figure 2, sodium lauryl sulfate reduces the solubility of compound 39 in the acid phase. At pH 4.5, the dissolution rate is nearly independent of the amount of sodium lauryl sulfate, suggesting the absence of ionic interactions between sodium lauryl sulfate and compound 39.

[0546] Example 3 Pharmaceutical Composition The ingredients of the pharmaceutical composition examples are shown in Table 4. [Table 4]

[0547] The pharmaceutical composition was prepared by first passing the granulation and sodium lauryl sulfate through a 35 mesh screen. The screened materials, hydroxypropyl methylcellulose, and microcrystalline cellulose were added to a 250 mL bottle and attached to a V-blender. The formulation was blended for 5 minutes. Magnesium stearate, passed through a 35 mesh screen, was added, and the formulation was blended for an additional 1 minute to yield the pharmaceutical composition.

[0548] Example 4 Oral dosage form Oral tablets were prepared manually using a Piccola B / D tablet press equipped with 9 mm round tooling by compressing the pharmaceutical composition of Example 2 at a compression force of 1700 PSI to provide oral tablets having an average hardness of approximately 8 kP to 10 kP.

[0549] The oral tablet had a weight of approximately 250 mg and a thickness of approximately 4.1 mm.

[0550] Example 5 Dissolution profile of oral dosage forms A two-stage dissolution apparatus was used to measure the dissolution profile of the tablets.

[0551] In the first step, the tablets were immersed in the dissolution medium 0.1 N HCl for 1 hour.

[0552] The dissolution medium was then immediately added to 50 mM acetate buffer at pH 4.5 immediately after the 1-hour sampling by adding 100 mM acetate buffer with the appropriate pH, and continued for 18 hours. The dissolution apparatus conditions are shown in Table 5. [Table 5]

[0553] Dissolution profiles showing the amount of compound (39) released over time for tablets prepared using pharmaceutical compositions (A), (B), and (C) are shown in FIG.

[0554] Example 6 modified release dosage form Modified-release tablets were first prepared by preparing a granulation of Compound 39 and hydroxypropyl methylcellulose E3 (Pharmacoat® 603). The granulation contained 98% Compound 39. The amounts of granulation, hydroxypropyl methylcellulose, sodium lauryl sulfate, and microcrystalline cellulose listed in Table 6 were combined, mixed using a V-blender, and sieved through a 35-mesh screen. The sieved formulation was then blended for 20 minutes using a V-blender. Magnesium stearate was sieved through a 35-mesh screen and added to the blended formulation. The formulation with the added magnesium stearate was blended for an additional 2 minutes. [Table 6]

[0555] Compound 39 and HPMC E3 do not constitute granules. The average particle diameter of the blended formulation was approximately 45 μm to 110 μm, as determined using sieve analysis or laser diffraction. Specific properties of the blended formulation are shown in Table 7. [Table 7]

[0556] Bulk density was determined using a bulk density cylinder.

[0557] Angle of repose is USP <1174> It was decided in accordance with the

[0558] Inherent fluidity is USP <1174> was determined using a Flodex™ instrument according to

[0559] Tablets were prepared using a Piccola B / D tablet press equipped with 9 mm tooling, a press speed of 20 RPM, and a compression force of 28 kN. The tablets had an average weight of 251 mg, an average hardness of 6.3 kP to 6.5 kP, an average thickness of 3.63 mm to 3.75 mm, and a friability of 0.1%.

[0560] Hardness is measured using diametral compression, USP <1217> It was decided in accordance with the

[0561] Friability was determined using a sonic sieve.

[0562] Each modified-release tablet contained 43% by weight or 107.75 mg of compound (39), equivalent to 58.3 mg of esketamine.

[0563] The two-phase dissolution profile for the tablets is shown in FIG.

[0564] A two-phase dissolution profile for the tablets was obtained using a USP1 dissolution apparatus. First, the tablets were added to 500 mL of 0.1 N hydrochloric acid solution and stirred at 100 RPM for 1 hour at 37°C. Samples (1 mL) were collected at 0, 0.5, and 1 hour. The acid solution was then replaced with 1,000 mL of 50 mM pH 4.5 acetate buffer, and the tablets were stirred at 100 RPM for up to 24 hours at 37°C. Samples (1 mL) were collected at 1.5, 2, 3, 4, 6, 8, 12, 16, 20, and 24 hours. Solution samples were collected at intervals, and the concentration of compound 39 was measured using high-pressure liquid chromatography-mass spectrometry.

[0565] As shown in Figure 1, the MR1 tablet is characterized by a relatively intermediate release rate, the MR2 tablet is characterized by a fast release rate, and the MR3 tablet is characterized by a slow release rate.

[0566] As shown in Figure 3, the dissolution profile exhibited a zero-order release profile.

[0567] Example 7 Ketamine / Pharmacokinetics The pharmacokinetics of ketamine after oral administration of modified-release tablets was determined.

[0568] Participants in each study portion were required to fast overnight for at least 10 hours (clear fluids were allowed) and were randomized on Day 1 prior to study drug administration. Fasting was required for 4 hours post-dose. Blood samples for pharmacokinetic measurements were collected immediately before dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24, 36, 42, and 48 hours post-dose.

[0569] Plasma concentrations of compound (39), esketamine, and noresketamine were determined using a validated liquid chromatography-mass spectrometry method.

[0570] The first study was an open-label, sequential, crossover evaluation of a single 100 mg oral dose of compound (39) in immediate-release (IR) and modified-release (MR) prototype formulations. Twelve healthy participants received one dose (IR capsule or one of three MR tablets: MR1, MR2, and MR3) in the morning every other day (48 hours between doses). The 12 participants were randomly assigned to one of four formulation test sequences (ABCD, BCDA, CDAB, DABC). Participants received the dose in the mornings of days 1, 3, 5, and 7, for a total of four days.

[0571] The pharmacokinetic profiles for esketamine and noresketamine after oral administration of a modified-release tablet containing 100 mg of Compound 39 are shown in Figures 4A and 4B, respectively. Pharmacokinetic parameters are summarized in Figure 5.

[0572] In the second study, five cohorts of eight participants each were randomized to six participants receiving a dose of compound 39 and two participants receiving a placebo. Active participants received escalating oral doses of compound 39 ranging from 100 to 400 mg in one of three modified-release tablets.

[0573] Modified-release tablets (MR1 tablet dosage form) containing 100 mg, 200 mg, 300 mg, or 400 mg of Compound (39) were administered once daily for 7 days to groups of six fasting healthy subjects.

[0574] The pharmacokinetic profiles of mean (+ / - SEM) plasma esketamine concentrations after administration of modified-release tablets containing 100 mg, 200 mg, 300 mg, or 400 mg of Compound (39) during the first day are shown in Figure 6A and during the seventh day of the study in Figure 6B.

[0575] The pharmacokinetic profiles of mean (+ / - SEM) plasma noresketamine concentrations after administration of a modified-release tablet containing 200 mg of Compound (39) during the first day are shown in Figure 7A and during the seventh day of the study in Figure 7B.

[0576] Pharmacokinetic parameters of the plasma esketamine and plasma noresketamine concentration-time profiles shown in Figures 6A-7B are shown in Tables 8-11. [Table 8] [Table 9] [Table 10] [Table 11]

[0577] Adverse events were monitored following oral administration of the tablet dosage form to subjects. Common adverse events observed during intranasal administration of esketamine include sedation, dissociation, elevated blood pressure, and cognitive impairment. The number of adverse events observed following oral administration of 100 mg of compound 39 in IR, MR1, MR2, and MR3 tablets is shown in Table 12. The number of adverse events is associated with a higher Cmax and immediate-release tablets. [Table 12]

[0578] Certain pharmacokinetic parameters for esketamine and noresketamine following oral administration of equimolar doses of compound (39) and esketamine are compared in Table 13. [Table 13]

[0579] Finally, it should be noted that there are alternative ways of implementing the embodiments disclosed herein, and therefore the present embodiments are illustrative and not limiting, and the claims are not to be limited to the details given herein, but may be modified within the scope and equivalents thereof.

Claims

1. 1. A pharmaceutical composition comprising: (a) a compound of formula (1), 【Chemistry 1】 or a pharmaceutically acceptable salt thereof, wherein: R １ is hydrogen and C １－６ alkyl, R ２ is selected from a moiety of formula (2), a moiety of formula (3), a moiety of formula (4), and a moiety of formula (5), 【Chemistry 2】 During the ceremony, R ３ is hydrogen, C １－６ Alkyl, C ７－１２ Alkyl arenes and substituted C ７－１２ selected from alkylarenes, R ４ is hydrogen and C １－６ alkyl, R5 is hydrogen, C １－６ alkyl, —C(═O)—R10, and —C(═O)—O—R10, wherein R １０ is C １－６ Alkyl, C ３－６ Cycloalkyl, and —CF ３ is selected from R ６ is C １－６ Alkyl and C １－６ alkoxy; n is an integer from 0 to 3, R7 is hydrogen, C １－６ Alkyl, —C(═O)—R11, and —C(═O)—O—R １０ is selected from: R １０ is C １－６ Alkyl and C ３－６ cycloalkyl; R １１ is -NH ２ , -CF ３ , C １－６ Alkyl, and C ３－６ cycloalkyl; R ９ is hydrogen and C １－３ a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of alkyl, (b) a controlled release polymer; and (c) an anionic sulfate / sulfonate surfactant.

2. The compounds of formula (1) are 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (3) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetylglycinate (62): 【Transformation 3】 【Chemistry 4】 or a pharmaceutically acceptable salt thereof.

3. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (6) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl 2-(3-methyloxetan-3-yl)acetate (63): 【Transformation 5】 【Transformation 6】 or a pharmaceutically acceptable salt thereof.

4. The compound of formula (1) is (S)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (22) and (R)-(((1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyl 2-(3-methyloxetan-3-yl)acetate (66): 【Transformation 7】 【Transformation 8】 or a pharmaceutically acceptable salt thereof.

5. The compound of formula (1) is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39) and ((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (65): 【Chemistry 9】 【Chemistry 10】 or a pharmaceutically acceptable salt thereof.

6. The compounds of formula (1) are 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (58) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethyl acetyl-L-leucinate (71): 【Chemistry 11】 【Chemistry 12】 or a pharmaceutically acceptable salt thereof.

7. The compound of formula (1) is 1-((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethylacetyl-L-alloisoleucinate (59) and 1-((((R)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)ethylacetyl-L-alloisoleucinate (72): 【Chemistry 13】 【Chemistry 14】 or a pharmaceutically acceptable salt thereof.

8. 2. The pharmaceutical composition according to claim 1, wherein the compound of formula (1) is ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39) or a pharmaceutically acceptable salt thereof.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the compound of formula (1) comprises a hydrochloride salt.

10. The pharmaceutical composition according to any one of claims 1 to 8, wherein the compound of formula (1) comprises a free base.

11. 11. The pharmaceutical composition according to any one of claims 1 to 10, wherein the compound of formula (1) or a pharmaceutically acceptable salt thereof has a higher solubility in 0.1 N hydrochloride salt than in 50 mM acetate buffer at pH 4.

5.

12. 12. The pharmaceutical composition of any one of claims 1 to 11, wherein the pharmaceutical composition comprises granules, the granules comprising more than 95% by weight of the compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein the weight percentage is based on the total weight of the granules.

13. 13. The pharmaceutical composition of claim 12, wherein the granules comprise a granule binder.

14. 14. The pharmaceutical composition of claim 13, wherein the granule binder comprises hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, or a combination of any of the foregoing.

15. 15. The pharmaceutical composition of claim 14, wherein the granule binder comprises hydroxypropyl methylcellulose.

16. 16. The pharmaceutical composition of claim 15, wherein the hydroxypropyl methylcellulose is characterized as a 2910 substitution type and characterized by a viscosity of 3 mPa x sec in a 2 wt% aqueous solution at 20°C.

17. 17. The pharmaceutical composition of any one of claims 13 to 16, wherein the granules comprise 0.5% to 5.0% by weight of the granule binder, the weight percentage being based on the total weight of the granule.

18. The granules are 97% to 99% by weight of the compound of formula (1) or a pharmaceutically acceptable salt thereof; 1% to 3% by weight of said granule binder; The pharmaceutical composition of any one of claims 12 to 17, wherein the weight percentages are based on the total weight of the granules.

19. The pharmaceutical composition according to any one of claims 12 to 18, wherein the granules have an average diameter of from 100 μm to 500 μm.

20. 20. The pharmaceutical composition of any one of claims 1 to 19, wherein the pharmaceutical composition comprises 35% to 55% by weight of the granules, the weight percentages being based on the total weight of the pharmaceutical composition.

21. 21. The pharmaceutical composition of any one of claims 1 to 20, wherein the controlled release polymer comprises a carbomer copolymer, shellac, a carbomer homopolymer, hypromellose (hydroxypropyl methylcellulose) polymer, a carbomer interpolymer, sodium carboxymethylcellulose, carrageenan, cerabrate, ethylcellulose, glyceryl monooleate, pregelatinized modified starch, glyceryl monostearate, guar gum, hydroxypropyl betadex, hydroxypropyl cellulose, polyethylene oxide, polyvinyl acetate dispersion, sodium alginate, pregelatinized starch, xanthan gum, alginic acid, ethyl acrylate / methyl methacrylate copolymer, acrylic acid / allylsucrose polymer, acrylic acid / allylpentaerythritol polymer, acrylic acid / alkyl acrylate / allylpentaerythritol copolymer, or a combination of any of the foregoing.

22. 21. The pharmaceutical composition of any one of claims 1 to 20, wherein the controlled release polymer comprises hydroxypropyl methylcellulose.

23. 23. The pharmaceutical composition of claim 22, wherein the hydroxypropyl methylcellulose is characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 in 2% water at 25°C, a hydroxypropoxyl content of 7.5% to 9.5%, and a viscosity of 80 mPa-s (cP) to 120 mPa-s (cP) as a 2% aqueous solution at 20°C.

24. 24. The pharmaceutical composition of claim 22 or 23, wherein the hydroxypropyl methylcellulose is characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 in 2% water at 25°C, a hydroxypropoxyl content of 7.5% to 9.5%, and a viscosity (Brookfield) of 2,600 cP mPa-s to 5,000 cP mPa-s as a 2% aqueous solution at 20°C.

25. The hydroxypropyl methylcellulose 50% to 100% by weight of hydroxypropyl methylcellulose characterized by a methoxyl content of 22% to 24%, a pH of 5 to 8 in 2% water at 25°C, a hydroxypropoxyl content of 7.5% to 9.5%, and a viscosity of 80 mPa-s (cP) to 120 mPa-s (cP) as a 2% aqueous solution at 20°C; and 0% to 50% by weight of hydroxypropyl methylcellulose characterized by a 22% to 24% methoxyl content, a pH of 5 to 8 in 2% water at 25°C, a hydroxypropoxyl content of 7.5% to 9.5%, and a viscosity (Brookfield) of 2,600 cP mPa-s to 5,000 cP mPa-s as a 2% aqueous solution at 20°C; 25. The pharmaceutical composition of any one of claims 22 to 24, wherein the weight percentages are based on the total weight of the hydroxypropyl methylcellulose.

26. 26. The pharmaceutical composition of any one of claims 1 to 25, wherein the pharmaceutical composition comprises 10% to 60% by weight of the controlled release polymer, wherein the weight percentage is based on the total weight of the pharmaceutical composition.

27. 27. The pharmaceutical composition of any one of claims 1 to 26, wherein the anionic sulfate / sulfonate surfactant is characterized by a critical micelle concentration of 2 g / L to 3 g / L (6.9 mmol / L to 10.4 mmol / L) at 20°C.

28. 28. The pharmaceutical composition of any one of claims 1 to 27, wherein the anionic sulfate / sulfonate surfactant comprises sodium lauryl sulfate.

29. 29. The pharmaceutical composition of claim 28, wherein the sodium lauryl sulfate is characterized by a critical micelle concentration of 2.2 g / L to 2.5 g / L at 20°C.

30. 30. The pharmaceutical composition of any one of claims 1 to 29, wherein the pharmaceutical composition comprises 5% to 15% by weight of the anionic sulfate / sulfonate surfactant, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

31. The pharmaceutical composition of any one of claims 1 to 30, wherein the pharmaceutical composition comprises a filler material.

32. 32. The pharmaceutical composition of claim 31, wherein the filler comprises microcrystalline cellulose.

33. 33. The pharmaceutical composition of claim 31 or 32, wherein the pharmaceutical composition comprises 5% to 35% by weight of the filler, wherein the weight percentage is based on the total weight of the pharmaceutical composition.

34. The pharmaceutical composition of any one of claims 1 to 33, wherein the pharmaceutical composition comprises a lubricant.

35. 35. The pharmaceutical composition of claim 34, wherein the lubricant comprises magnesium stearate.

36. 36. The pharmaceutical composition of claim 34 or 35, wherein the pharmaceutical composition comprises 0.1% to 1.5% by weight of the lubricant, the weight percentage being based on the total weight of the pharmaceutical composition.

37. The pharmaceutical composition comprises: 30% to 60% by weight of the granules; 10% to 60% by weight of the controlled release polymer; 5% to 15% by weight of said anionic sulfate / sulfonate surfactant; 37. The pharmaceutical composition of any one of claims 1 to 36, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

38. The pharmaceutical composition comprises: 35% to 55% by weight of the granules; 20% to 40% by weight of the controlled release polymer; 10% to 20% by weight of a filler; 5% to 15% by weight of said anionic sulfate / sulfonate surfactant; 0.1% to 1.0% by weight of a lubricant; 37. The pharmaceutical composition of any one of claims 1 to 36, wherein the weight percentages are based on the total weight of the pharmaceutical composition.

39. the controlled release polymer comprises hydroxypropyl methylcellulose; the filler comprises microcrystalline cellulose; the anionic sulfate / sulfonate surfactant comprises sodium lauryl sulfate; 39. The pharmaceutical composition of claim 38, wherein the lubricant comprises magnesium stearate.

40. The pharmaceutical composition according to any one of claims 1 to 39, wherein the pharmaceutical composition comprises a granulation.

41. 40. The pharmaceutical composition of any one of claims 1 to 39, wherein the pharmaceutical composition comprises a tablet oral dosage form.

42. An oral dosage form prepared from the pharmaceutical composition of any one of claims 1 to 41.

43. An oral dosage form comprising the pharmaceutical composition of any one of claims 1 to 41.

44. 44. The oral dosage form of claim 43, wherein the oral dosage form comprises a solid oral dosage form.

45. 44. The oral dosage form of claim 43, wherein the oral dosage form comprises a tablet.

46. 46. ​​The oral dosage form of any one of claims 42 to 45, wherein the oral dosage form comprises 25 mg to 400 mg of the compound of formula (1) or a pharmaceutically acceptable salt thereof.

47. 10. The oral dosage form of claim 1, 35% to 55% by weight of the compound of formula (1); 0.5% to 1.5% by weight of hydroxypropyl methylcellulose E3; 47. The oral dosage form of any one of claims 42 to 46, wherein the weight percentages are based on the total weight of the oral dosage form.

48. 10. The oral dosage form of claim 1, 35% to 55% by weight of the compound of formula (1); 0.5% to 1.5% by weight of hydroxypropyl methylcellulose E3; 20% to 40% by weight of a controlled release polymer; 10% to 20% by weight of microcrystalline cellulose; 5% to 15% by weight of sodium lauryl sulfate; 0.1% to 1.0% by weight of magnesium stearate; 47. The oral dosage form of any one of claims 42 to 46, wherein the weight percentages are based on the total weight of the tablet dosage form.

49. 49. The oral dosage form of claim 48, wherein the controlled release polymer is selected from hydroxypropyl methylcellulose K100 Premium LV DC2, hydroxypropyl methylcellulose K4M Premium DC2, or a combination thereof.

50. 50. The oral dosage form of any one of claims 46 and 49, wherein the compound of formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39).

51. 50. The oral dosage form of any one of claims 46 and 49, wherein the compound of formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39) HCl.

52. the tablet oral dosage form exhibits a zero order release profile of the compound of formula (1) or a pharmaceutically acceptable salt thereof over a 6 hour duration in a two-stage dissolution medium as determined using a USP I dissolution apparatus at a stirring rate of 100 RPM and a temperature of 37°C; the first step comprising soaking the tablet dosage form in 0.1 N hydrochloric acid for 1 hour; 52. The oral dosage form of any one of claims 45 to 51, wherein a second step comprises immersing said tablet dosage form in 50 mM acetate buffer at pH 4.5 for said duration.

53. The tablet oral dosage form is characterized by a dissolution profile of the compound of formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37°C, 20% to 40% of the compound of formula (1) is released in 2 hours; 30% to 50% of the compound of formula (1) is released in 4 hours; 70% to 80% of the compound of formula (1) is released in 8 hours; 80% to 100% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours; the first step comprising soaking the oral dosage form in 0.1 N hydrochloric acid for 1 hour; a second step comprising immersing said oral dosage form in 50 mM acetate buffer at pH 4.5 for said duration; 53. The oral dosage form of claim 52, wherein the percentage (%) is based on the total amount of the compound of formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form before the immersion.

54. The tablet oral dosage form is characterized by a dissolution profile of the compound of formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37°C, 30% to 40% of the compound of formula (1) is released in 2 hours; 50% to 70% of the compound of formula (1) is released in 4 hours; 70% to 90% of the compound of formula (1) is released in 8 hours; More than 90% of the compound of formula (1) is released in 12 hours; the first step comprising soaking the oral dosage form in 0.1 N hydrochloric acid for 1 hour; a second step comprising immersing said oral dosage form in 50 mM acetate buffer at pH 4.5 for said duration; 53. The oral dosage form of claim 52, wherein the percentage (%) is based on the total amount of the compound of formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form before the immersion.

55. The tablet oral form is characterized by a dissolution profile of the compound of formula (1) or a pharmaceutically acceptable salt thereof in a two-stage dissolution medium as determined using a USP I dissolution apparatus at an agitation rate of 100 RPM and a temperature of 37°C, 15% to 25% of the compound of formula (1) is released in 2 hours; 20% to 35% of the compound of formula (1) is released in 4 hours; 50% to 60% of the compound of formula (1) is released in 8 hours; 70% to 85% of the compound of formula (1) is released in 12 hours; 80% to 100% of the compound of formula (1) is released in 16 hours; the first step comprising soaking the oral dosage form in 0.1 N hydrochloric acid for 1 hour; a second step comprising immersing said oral dosage form in 50 mM acetate buffer at pH 4.5 for said duration; 53. The oral dosage form of claim 52, wherein the percentage (%) is based on the total amount of the compound of formula (1) or a pharmaceutically acceptable salt thereof in the oral dosage form before the immersion.

56. 53. The oral dosage form of claim 52, wherein the two-phase dissolution profile is bioequivalent to any one of the dissolution profiles shown in Figure 1.

57. Following oral administration of a tablet formulation containing 100 mg of the compound of formula (1) to a group of fasted healthy subjects: the AUC0-inf of the plasma esketamine concentration is between 60 h × ng / mL and 120 h × ng / mL; and / or 57. The oral dosage form of any one of claims 45 to 56, wherein the AUC0-inf of the plasma noresketamine concentration is from 850 hr×ng / mL to 1,000 hr×ng / mL.

58. Following oral administration of a tablet oral dosage form containing 100 mg of the compound of formula (1) to a group of fasted healthy subjects: a maximum plasma esketamine concentration of 5 ng / mL to 10 ng / mL; and / or 58. The oral dosage form of any one of claims 45 to 57, wherein the maximum plasma norketamine concentration is from 40 ng / mL to 80 ng / mL.

59. Following oral administration of a tablet oral dosage form containing 100 mg to 400 mg of the compound of formula (1) to a population of fasted healthy subjects: maximum plasma esketamine concentration is less than 30 ng / mL; and / or 59. The oral dosage form of any one of claims 45 to 58, wherein the maximum plasma noresketamine concentration is less than 250 ng / mL.

60. following oral administration of a tablet oral dosage form containing 100 mg to 400 mg of the compound of formula (1) to a population of fasted healthy subjects, the ratio of Cmax / Cave (0 h to 24 h) of esketamine is between 2 and 4; Cmax is the maximum plasma esketamine concentration; 60. The oral dosage form of any one of claims 45-59, wherein Cave(0h-24h) is the mean plasma esketamine concentration from 0 hours to 24 hours after oral administration of the tablet dosage form.

61. following oral administration of a tablet oral dosage form containing 100 mg to 400 mg of the compound of formula (1) to a population of fasted healthy subjects, the ratio of Cmax / Cave (0 h to 24 h) of esketamine is 2.5 to 3.5; Cmax is the maximum plasma esketamine concentration; 61. The oral dosage form of any one of claims 45 to 60, wherein Cave(0h-24h) is the mean plasma esketamine concentration from 0 hours to 24 hours after oral administration of the tablet dosage form.

62. following oral administration of a tablet oral dosage form containing 100 mg to 400 mg of the compound of formula (1) to a population of fasted healthy subjects, the ratio of Cmax / Cave (0 h to 24 h) of noresketamine is between 1 and 3; Cmax is the maximum plasma noresketamine concentration; 62. The oral dosage form of any one of claims 45-61, wherein Cave(0h-24h) is the mean plasma noresketamine concentration from 0 hours to 24 hours after oral administration of the tablet dosage form.

63. following oral administration of a tablet oral dosage form containing 100 mg to 400 mg of the compound of formula (1) to a population of fasted healthy subjects, the ratio of Cmax / Cave (0 h to 24 h) of noresketamine is 1.5 to 2.5; Cmax is the maximum plasma noresketamine concentration; 63. The oral dosage form of any one of claims 45 to 62, wherein Cave(0h-24h) is the plasma concentration of noresketamine from 0 hours to 24 hours after oral administration of the tablet dosage form.

64. 64. The oral dosage form of any one of claims 52 to 63, wherein the compound of formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39).

65. 64. The oral dosage form of any one of claims 52 to 63, wherein the compound of formula (1) comprises ((((S)-1-(2-chlorophenyl)-2-oxocyclohexyl)(methyl)carbamoyl)oxy)methyldimethyl-L-valinate (39) HCl.

66. A kit comprising a pharmaceutical composition according to any one of claims 1 to 41 or an oral dosage form according to any one of claims 42 to 65.

67. 66. A method of treating a disease in a patient, comprising orally administering a therapeutically effective amount of the pharmaceutical composition of any one of claims 1 to 41 or the oral dosage form of any one of claims 42 to 65 to a patient in need of such treatment, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

68. 68. The method of claim 67, wherein the disease is depression.

69. 69. The method of claim 68, wherein the depression is selected from major depressive disorder, dysthymia, persistent depressive disorder, bipolar disorder, seasonal affective disorder, psychotic depression, perinatal depression, premenstrual dysphoric disorder, situational depression, atypical depression, treatment-resistant depression, endogenous depression, cyclothymic disorder, and severe mood dysregulation disorder.

70. 69. The method of claim 68, wherein the depression is major depressive disorder.

71. 42. A method of treating a disease in a patient, comprising orally administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical composition of any one of claims 1 to 41, wherein the disease is treated by inhibiting the NMDA receptor.

72. 66. A method of treating a disease in a patient, comprising orally administering a therapeutically effective amount of the oral dosage form of any one of claims 42 to 65 to a patient in need of such treatment, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

73. 73. The method of claim 72, wherein the disease is depression.

74. 74. The method of claim 73, wherein the depression is selected from major depressive disorder, dysthymia, persistent depressive disorder, bipolar disorder, seasonal affective disorder, psychotic depression, perinatal depression, premenstrual dysphoric disorder, situational depression, atypical depression, treatment-resistant depression, endogenous depression, cyclothymic disorder, and severe mood dysregulation disorder.

75. 74. The method of claim 73, wherein the depression is major depressive disorder.

76. 66. A method of treating a disease in a patient, comprising orally administering a therapeutically effective amount of the oral dosage form of any one of claims 42 to 65 to a patient in need of such treatment, wherein the disease is treated by inhibiting the NMDA receptor.

77. 42. Use of the pharmaceutical composition of any one of claims 1 to 41 in the manufacture of a medicament for treating a disease in a patient, wherein the disease is selected from a neurological disease, a psychiatric disease, and pain.

78. 78. The use of claim 77, wherein the disease is depression.

79. 79. The use of claim 78, wherein the depression is selected from major depressive disorder, dysthymia, persistent depressive disorder, bipolar disorder, seasonal affective disorder, psychotic depression, perinatal depression, premenstrual dysphoric disorder, situational depression, atypical depression, treatment-resistant depression, endogenous depression, cyclothymic disorder, and severe mood dysregulation disorder.

80. 79. The use of claim 78, wherein the depression is major depressive disorder.

81. 42. Use of a pharmaceutical composition according to any one of claims 1 to 41 in the manufacture of a medicament for treating a disease in a patient, wherein the disease is treated by inhibiting NMDA receptors.

Images